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PLAN B FOR THE FDA: A NEED FOR A THIRD CLASS OF
DRUG REGULATION IN THE UNITED STATES INVOLVING
A "PHARMACIST-ONLY' CLASS OF DRUGS
MATTHEW J. SEAMON*
INTRODUCTION
On May 6, 2004, the Food and Drug Administration (FDA)
rejected an application to market and sell Plan B® emergency
contraception (EC) without a prescription,' despite an overwhelming
recommendation from a joint advisory committee.2 This decision
triggered the most heated political debate involving the FDA since
their refusal to approve thalidomide in 1962. 3 Proponents of the
FDA's decision describe it as a well-reasoned ruling by an elected
administration, a pro-life victory, and justice in public welfare.4
Opponents characterize this decision as a dangerous furtherance of
* Matthew J. Seamon, Pharm.D., is an Assistant Professor of Pharmacy Practice
in Drug Information at Nova Southeastern University College of Pharmacy. Dr. Seamon
is also a part-time law student at the Shepard Broad Law Center, Nova Southeastern
University. Dr. Seamon received his Pharm.D. from the University of Michigan College
of Pharmacy in Ann Arbor, Michigan, and completed a Drug Information Specialized
Residency at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr.
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1. U.S. GOV'T ACCOUNTABILITY OFFICE, FOOD & DRUG ADMIN.; DECISION PROCESS TO
DENY INITIAL APPLICATION FOR OVER-THE-COUNTER MARKETING OF THE EMERGENCY
CONTRACEPTIVE DRUG PLAN BWAs UNUSUAL 2-3 (2005), available at http://www.gao.gov/
new.items/d06109.pdf [hereinafter GAO UNUSUAL DECISION REPORT].
2. Food & Drug Admin., Ctr. for Drug Evaluation & Res., Nonprescription Drugs
Advisory Committee (NDAC) in Joint Session with the Advisory Committee for
Reproductive Health Drugs (ACRHD) Meeting (Dec. 16,2003) (unpublished manuscript),
available at http://www.fda.gov/ohrms/dockets/ac/03/transcripts/4015Tl.doc [hereinafter
Joint Committee Report]. The Joint Advisory Committee voted twenty-three to four to
approve Plan B® for use without a prescription. Id. at 395.
3. In 1960, the FDA delayed approval of thalidomide by requesting more clinical
data regarding its safety, despite tremendous political pressure from the manufacturer.
David M. Keifer, How an Iron- Willed FDA Officer Averted a Birth Defect Disaster, 6
TODAY'S CHEMIST WORK 92 passim (1997) [hereinafter Thalidomide]. Thalidomide was
widely available throughout the world without a prescription to treat morning sickness,
as a sleeping aid, and was even coined West Germany's favorite "baby-sitter." Id. at 92.
While thalidomide was pending approval in the United States, worldwide surveillance
revealed the drug was extremely teratogenic causing a number of children to be born
with phocomelia (Greek for seal limb) and the drug was not approved. Id. at 93, 96.
4. See, e.g., Jenni Parker, Pro-Lifers, Pro-Family Groups Hail FDA Decision
Rejecting OTC Morning-After Pill, AGAPEPRESS.ORG, May 7, 2004, available at
http://headlines.agapepress.org/archive/5/72004b.asp.
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social conservatism, propaganda "trumping" science, and political
ideology run amuck.5
Clearly this situation is complex. The issues that surround EC
are emotionally charged and involve a sharp split among the
American public.6 For example, a number of states have established
their own regulatory system allowing EC to be available without a
prescription, undermining the authority of the FDA.' On the other
hand, pharmacists may conscientiously object to selling it, under-
mining public health.'
At the epicenter of this debate lies the FDA, an agency compel-
led to make a decision that lost the confidence of many of the people
they were trying to protect.9 An alternate solution may have been
overlooked. Congress should establish a "pharmacist-only" class of
drugs in this country allowing the sale of EC without a physician's
prescription under required consultation with a pharmacist.'
Part I of this article reviews the historical, scientific, political,
legal, and bioethical issues surrounding EC in the United States. It
also introduces the focus of this discussion and the only EC product
5. See, e.g., David A. Grimes, Emergency Contraception: Politics Trumps Science at
the U.S. Food and Drug Administration, 104 AM. C. OBSTETRICIANS & GYNECOLOGISTS
220, 220 (2004).
6. The issue that surrounds emergency contraception is, essentially, abortion. Pro-
choice advocates view EC as an important option, while pro-life advocates view it as
abortion and essentially murder.
7. See Heather M. Field, Increasing Access to Emergency Contraceptive Pills
Through State Law Enabled Dependent Pharmacist Prescribers, 11 UCLA WOMEN'S L.J.
141, 229-31 (2000); Tina R. Raine et al., Direct Access to Emergency Contraception
Through Pharmacies and Effect on Unintended Pregnancy and STIs, 293 JAMA 54, 54
(2005). See also Grimes, supra note 5, at 221 ("Women in California and ... other states
can buy emergency contraception at pharmacies without first seeing a physician for a
prescription."); Morning After Pill: OTC?, CBSNEWS.COM, Aug. 9, 2005, http://www.
cbsnews.com/stories/2005/08/09/health/main767140.shtml.
8. See AM. PHARMACISTS ASS'N, HOUSE OF DELEGATES, 2004 REPORT OF THE POLICY
REVIEW COMMI'rEE: PHARMACISTS CONSCIENCE CLAUSE 10 (2004), available at
http://www.aphanet.org/AM/Template.cfm?Section=Search&section=AboutAPhAl&
template=/CM/ContentDisplay.cfm&ContentFileID=224 [hereinafter APHA CONSCIENCE
CLAUSE]. The APhA "recognizes the individual pharmacist's right to exercise
conscientious refusal and supports the establishment of systems to ensure patient's
access to legally prescribed therapy without as compromising the pharmacist's right of
conscientious refusal." Id.
9. See Jeffrey M. Drazen et al., The FDA, Politics, and Plan B, Editorial, 350 NEW
ENG. J. MED. 1561, 1561-62 (2004).
10. A pharmacist-only class of drugs includes drugs that are available without a
prescription, but can be obtained only in a pharmacy and sometimes dispensed only by
a pharmacist. U.S. GEN. ACCOUNTING OFFICE, REPORT TO THE RANKING MINORITY
MEMBER, COMMITTEE ON COMMERCE, HOUSE OF REPRESENTATIVES, NONPRESCRIPTION
DRUGS: VALUE OF A PHARMACIST CONTROLLED CLASS HAS YET To BE DEMONSTRATED 11,
GAO/PEMID-95-12 (1995), available at http://www.gao.gov/archive/1995/pe95012.pdf
[hereinafter GAO REPORT].
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currently available in this country, Plan B®." Part II discusses the
regulatory framework surrounding prescription and nonprescription
medications and how a drug undergoes an "Rx to OTC Switch."' 2
Part III explores the issues surrounding Barr Pharmaceuticals,
Inc.'s application for Plan B® nonprescription use and the FDA's
controversial decision to reject it. It also presents a discussion of
statewide protocols and collaborative practice agreements currently
in place to allow EC, such as Plan B®, without a prescription in
select states. 13 Part IV of this article describes the establishment of
a third class of drug regulation in this country: a pharmacist-only
class of drugs. Part V examines the practical limitations to a
pharmacist-only class of drug regulation for EC and the future of
Plan B® in the United States.
I. EMERGENCY CONTRACEPTION
A. Background
Emergency contraception (EC) is defined as the targeted use of
hormone therapy, or use of an intrauterine device, specifically de-
signed to prevent pregnancy following unprotected intercourse or
contraceptive failure. 4 EC is also indicated for victims of sexual
assault and women exposed to known teratogens. 5 EC works by
preventing ovulation or inhibiting implantation of a fertilized ovum,
both of which are necessary for pregnancy to occur.1
6
The first widely recognized reference to birth control involved
the withdrawal method mentioned in the Bible's book of Genesis. v
11. Plan B® has been available since 1999 and has been the only drug available for
emergency contraception since 2004. National Family Planning & Reproductive Health
Ass'n, Emergency Contraception and Plan B®, http://www.nfprha.org/pac/factsheets/
planb.asp (last visited Mar. 11, 2006). For information concerning how Plan B® is
prescribed, see Barr Pharmaceuticals, Inc., Plan B® (levonorgestrel) U.S. Prescribing
Information (Feb. 2004), available at http://www.go2planb.com/PDF/PlanBPI.pdf
[hereinafter Plan B Prescribing Information]. See also infra notes 67-68 and
accompanying text.
12. "Rx to OTC Switch" refers to the regulatory process for changing a prescription
(Rx) drug to nonprescription (OTC). See Leland L. Price, Sweetening the Bitter Pill: Rx
to OTC Switches Via a Third Class of Drugs 7-9 (unpublished manuscript, available at
Harvard Law School Legal Electronic Document Archive, http://leda.law.harvard.
edulleda/datal15/lprice.pdf (last visited Mar. 22, 2006)).
13. See infra Part III.C.
14. David A. Grimes & Elizabeth G. Raymond, Emergency Contraception, 137
ANNALS INTERNAL MED. 180, 180 (2002).
15. Id. at 180 tbl.1.
16. Id. at 182.
17. See Genesis 38:9 (Holman Christian Standard) ("But Onan knew that the
offspring would not be his; so whenever he slept with his brother's wife, he released his
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Other, more novel approaches, have been documented since 1850
B.C. when women in Egypt used a combination of crocodile dung,
honey, and sodium carbonate to make vaginal suppositories, called
pessaries, to prevent pregnancy." In the 1700s, Giacomo Casanova,
the Venetian seducer, noted the use of half a lemon rind as a
cervical cap and used condoms as a form of contraception.19 He was
believed to prefer condoms made of lamb intestine." References
relating to post-coital contraception date back to at least 1500 B.C.
when women tried sneezing, hopping, dancing, and jumping after
intercourse to prevent pregnancy. 2' Although these practices were
not effective, similarly amusing variations have continued through
this century, with reports from the 1930s through the 1960s of
women using Lysol® and Coca-Cola® as post-coital douches.22
EC is under a great transformation in this country. Over the
past fifty years, with the advent of synthetic estrogens and
progestins, women have had an increasing number of options to
prevent unwanted pregnancies. 2 Birth control pills, patches,
vaginal rings, and injections are available, even a chewable tablet
in spearmint flavor.24 Furthermore, the use of EC has been increas-
ing and physicians are now writing "advance prescriptions" for
women to keep on hand.25
semen on the ground so that he would not produce offspring for his brother."). See also
Genesis 38:10, which continues "What he did was evil in the Lord's sight, so He put him
to death also." Id.
18. Daniel DeNoon, Birth Control Timeline, WEBMD.COM, May 4, 2004, http:/www.
webmd.comcontent/article/71/81244.htm?printing-true.
19. Id.
20. Id.
21. June LaValleur, Emergency Contraception, 27 OBSTETRICS & GYNECOLOGY
CLINICS N. AM. 817, 818 (2000).
22. LaValleur, supra note 21, at 818; DeNoon, supra note 18.
23. Iris F. Litt, Placing Emergency Contraception in the Hands of Women, 293 JAMA
98, 98 (2005).
24. The following are examples of these birth control devices. Ortho Evra® is a
weekly contraceptive patch marketed by Ortho-McNeil Pharmaceutical, Inc. Ortho Evra
Home Page, http://www.orthoevra.com (last visited Mar. 22, 2006). NuvaRinge is a
monthly contraceptive vaginal ring manufactured by Organon. NuvaRing Home Page,
http://www.nuvaring.com/consumer/whatIsNuvaRing/indexflash.asp (last visited Mar.
22, 2006). Depo-Provera® is a contraceptive injection administered every 11 to 13 weeks
manufactured by Pfizer. Depo-Provera Home Page, http://www.depo-provera.coml
howitworks.asp (last visited Mar. 22,2006). Ovcon 35® is a spearmint flavored chewable
oral contraceptive marketed by Warner Chilcott Pharmaceuticals. Ovcon 35,
http://www.warnerchilcott.com/products/ovcon.php (last visited Mar. 22, 2006).
25. Certain doctors and chapters of Planned Parenthood provide patients with
prescriptions for emergency contraception at routine visits. They are instructed to take
these prescriptions to a pharmacy in case of an emergency. See Ann Carms, U.S. Web
Sites Let Women Obtain Emergency Contraceptive Pills- Reproductive Rights Advocates
Applaud Service - Elimination of Vsits with Doctor Concerns Opponents, WALL ST. J.
(Eur.), May 6, 2001, at 24.
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A number of renowned national healthcare organizations have
publicly advocated EC without a prescription, including the American
Medical Association, the American College of Obstetricians and
Gynecologists, the American Academy of Pediatrics, and the
American Academy of Family Physicians.26 An influential segment
of our culture, however, is strongly opposed to EC. Pro-life organiza-
tions such as the Family Research Council, Concerned Women for
America, and sects of the Catholic Church have strongly opposed the
attempted switch. 27 This dissension is readily apparent with the
latest Department of Justice Guidelines for treating sexual assault
victims, where mention of EC is conspicuously absent.28 Media
reports indicate that EC was included in earlier versions of the
protocol and purposefully omitted from the final one.29 One New
York congresswoman was even denied the opportunity to comment
on this glaring omission at a public hearing on the subject.3 °
Although EC is generally considered a recent phenomenon, oral
contraception has been used "off label" since 1974 as EC.31 This use
is seen primarily in hospitals, university health clinics, and, to a
26. Victoria S. Elliott, Doctors Assess Impact of Morning-After Pill Going OTC,
AMEDNEWS.COM, Jan. 19, 2004, http://www.ama-assn.org/amednews/2004/01/19/
h110119.htm. See also AMA Policy, HR-75.985 Access to Emergency Contraception,
available at http://www.ama-assn.org/apps/pfLnew/pfLonline?f-n-resultLink&doc=
policyfiles/HnE/H-75.985.HTM&S-t=75-985&catg=AMA/HnE&catg=AMA/
BnGnC&catg=AMA/DIR&&nth=l&&st-p=o&nth=l& (last visited Mar. 22, 2006).
27. Gina Kolata, Debate on Selling Morning-After Pill over the Counter, N.Y. TIMES,
Dec. 12, 2003, at Al. See also Donald W. Herbe, Note, The Right to Refuse: A Call for
Adequate Protection of a Pharmacist's Right to Refuse Facilitation of Abortion and
Emergency Contraception, 17 J. L. & HEALTH 77, 87 (2002).
28. See OFFICE OF VIOLENCE AGAINST WOMEN, U.S. DEP'T OF JUSTICE, A NATIONAL
PROTOCOL FOR SEXUAL ASSAULT MEDICAL FORENSIC EXAMINATIONS, ADULTS/
ADOLESCENTS, NCJ 206554 (2004), available at http://www.ncjrs.org/pdffilesl/
ovw/206554.pdf. This protocol "provides detailed guidelines for criminal justice and
health care practitioners in responding to the immediate needs of sexual assault
victims." Id. at iii. It emphasizes that "[c]ombining cutting edge response techniques
with collaboration among service providers will greatly enhance our ability to treat and
support victims." Id. There is no mention, however, of Plan B or EC in the protocol.
29. See American Civil Liberties Union, Take Action: Urge Congress to Support
Pregnancy Prevention Information for Rape Victims, https://secure.aclu.org/site/
Advocacy?pagename=homepage&page=UserAction&id=153 (last visited Mar. 22,2006).
30. See Press Release, Congresswoman Carolyn B. Maloney, Justice Department
Denies Member of Congress Ability to Speak or Submit Testimony at Public Hearing on
Health Treatment Protocol for Victims of Sexual Assault (Feb. 10, 2005), available at
http://maloney.house.gov/index.php?option=comcontent&task-view&id- 144&Itemid=61.
31. The Yuzpe method of birth control is named after the Canadian professor who
first identified its use, Albert Yuzpe. Food & Drug Admin. Notice, Prescription Drug
Products: Certain Combined Oral Contraceptives for Use as Postcoital Emergency
Contraception, 62 Fed. Reg. 8610 (Feb. 25, 1997) [hereinafter FDA Notice]. The Yuzpe
method consists of two doses separated by twelve hours and initiated within seventy-two
hours of unprotected intercourse. Id.; Litt, supra note 23, at 98.
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lesser extent, by physicians in private practice.32 Women were typ-
ically instructed to take two to five of their regular birth control pills
for two doses, 12 hours apart, following unprotected intercourse.
In 1997, the FDA declared this form of EC safe and effective for
women.34 EC has been formally available in this country since 1998
with a prescription,35 and is widely available throughout the world
without a prescription.36 Overall, there is a mounting trend toward
acceptance of EC.37 Furthermore, research in this area has grown
exponentially over the last decade,38 providing further evidence that
EC is safe and effective and poses no increased risk of sexually
transmitted diseases or pregnancy.39
The rate of unintended pregnancies is reaching epidemic pro-
portions, and the need for a reliable and widely accessible redress
is growing.4 ° An estimated 3.5 million unintended pregnancies occur
annually in this country, with one-third involving teenagers.4 In
fact, about twenty percent of all teenage girls who have sexual
intercourse become pregnant each year.42 Further estimates are that
fifty percent of unwanted pregnancies could be averted with EC,
43
thus greatly reducing the number of abortions performed. Moreover,
fewer than one-quarter of teenagers know anything about EC or
other options following unprotected intercourse.44 Two-thirds of the
teenage girls who were informed of the option said they would be
likely to use EC.4'
32. FDA Notice, supra note 31, at 8610.
33. See Grimes & Raymond, supra note 14, at 181 tbl.2.
34. FDA Notice, supra note 31; see also LaValleur supra note 21, at 818.
35. FDA Notice, supra note 31. For more information, see NOT-2-IATE.com, a
website operated by the Office of Population Research at Princeton Health Professionals.
NOT-2-LATE.com Home Page, http://ecprinceton.edu (last visited Mar. 22, 2006). This
website serves as an evidence-based resource for information on emergency contra-
ception. Id. It is a great source of information with references, educational and
promotional materials, and a local directory of providers available to prescribe EC. Id.
36. See Field, supra note 7, at 151.
37. See David A Grimes, Switching Emergency Contraception to Over-the-Counter
Status, 347 NEW ENG. J. MED. 846, 848 (2002).
38. A simple MEDLINE search using PubMed and the keywords "Emergency
Contraception" reveals that from 1980-1990 there is one article, from 1990-2000 there
are 321 articles, and from 2000-2004 there are 433 articles.
39. See, e.g., Raine et al., supra note 7, at 58-62.
40. David A. Grimes et al., Emergency Contraception Over-the-Counter: The Medical
and Legal Imperatives, 98 OBSTETRICS & GYNECOLOGY 151, 151 (2001).
41. Litt, supra note 23, at 98.
42. Suzanne F. Delbanco et al., Missed Opportunities: Teenagers and Emergency
Contraception, 152 ARCHIVES PEDIATRICS & ADOLESCENT MED. 727, 727 (1998).
43. Raine et al., supra note 7, at 54.
44. See Delbanco et al., supra note 42, at 729.
45. Id. at 730.
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The difference between EC and abortion is a nebulous, yet
important, distinction for many people and is based on highly
technical terminology.46 The consensus among the scientific and
medical communities is that EC is not abortifacient.47 The FDA, the
National Institutes of Health (NIH), and the American College of
Obstetricians and Gynecologists define abortion "only as disruption
of an implanted fertilized ovum."48 Accordingly, pregnancy occurs
only after implantation of the fertilized egg to the uterine wall.
Ovum (egg) and sperm each have twenty-three chromosomes.49
Upon ovulation, the ovum is released from the ovaries and travels
down the fallopian tube. ° Fertilization occurs when the sperm
attaches to a receptor on the ovum called the zona pellucida.51 At
this stage, a zygote is created, having a complete set of maternal
and paternal DNA (i.e., forty-six chromosomes)." It is not until the
fertilized ovum (i.e., zygote) actually implants in the uterine wall
that pregnancy is considered to occur.
The zygote then continues down the fallopian tube toward the
uterus where it divides into a ball of cells at around day two. 3 The
zygote then organizes itself into the morula around day three or four
while continuing to divide. 4 At approximately day six, the morula
enters the uterine cavity and develops into a blastocyst, a sphere-
shaped structure with both inner and outer cells.5 The inner cells
of the blastocyst, called the embryoblast, develop into the embryo
while the outer layer of cells, called the trophoblast, ultimately form
part of the placenta. 6 The embryo then implants in the uterine wall
46. This distinction is the basis for the debate between pro-life and pro-choice
advocates. Grimes, supra note 37, at 847.
47. Caroline Wellbery, Emergency Contraception: An Ongoing Debate, 70 AM. FAM.
PHYsICIAN 655, 655 (2004).
48. Id. (emphasis added); see also 45 C.F.R. § 46.202(f) (2005) (defining pregnancy as
"the period of time from implantation until delivery").
49. See Earl W. Stradtman, Jr., Genetics in Reproduction, in TEXTBOOK OF
REPRODUCTIVE MEDICINE 57, 57 (Bruce R. Carr & Richard E. Blackwell eds., Appleton
& Lange, 2d ed. 1998) (1993).
50. See Medline Plus Medical Encyclopedia, Fetal Development, http://www.nlm.
nih.gov/medlineplus/ency/article/002398.htm (last visited Mar. 22, 2006) [hereinafter
Fetal Development].
51. See William Byrd, Fertilization, Embryogenesis, and Implantation, in TEXTBOOK
OF REPRODUCTIVE MEDICINE, supra note 49, at 1, 5-6.
52. Stradtman, supra note 49, at 58.
53. See Fetal Development, supra note 50.
54. Id.
55. See Press Release, Nat'l Inst. of Health, Researchers Discover How Embryo
Attaches to the Uterus (Jan. 16, 2003), available at http://www.nichd.nih.gov/new/
releases/embryo.cfm.
56. Id.
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at approximately day seven, and at that point pregnancy occurs.57
It is important to note that not all fertilized ovum fully develop or
implant in the uterine wall.58
Whereas EC prevents pregnancy, abortion disrupts an already
established pregnancy.59 Thus, EC differs from other "morning
after" pills such as misoprostol, methotrexate, or mifepristone
(Mifeprex®, RU-486) in that these agents disrupt an already estab-
lished pregnancy and are considered abortifacients. ° To complicate
this controversy, morning after pills like mifepristone may also be
used in low doses to prevent pregnancy.6 '
Although this matter may be resolved with mere semantics, the
issue remains substantially more complex. Critics of the implanta-
tion distinction note that 'life' begins at conception.62 Under this
doctrine, EC is an abortifacient.63 Scientifically speaking, this
argument has merit, as a fertilized ovum has a full complement of
DNA.64 Suffice it to say, the distinction between abortion and
57. Id.; see also Wellbery, supra note 47, at 655.
58. See WILLIAMS OBSTETRICS 580-82 (F. Gary Cunningham et al. eds., Appleton &
Lange, 20th ed. 1999) (1930). Williams presents a theoretical discussion of reproductive
success and failure in healthy, young women. Approximately 5% of ovarian cycles fail to
produce an ovum, and an additional 7% produce an ovum that is not fertilizable. Id. at
580. Moreover, approximately 23% of fertilized ovum will fail to implant or are lost to
early pregnancy wastage. See id. at 582. Of the remaining clinical pregnancies,
approximately 10% will spontaneously abort with additional perinatal mortality of 1%.
Id. at 581. Ectopic pregnancy is another complication involving early loss. This is where
a fertilized ovum implants outside of the uterus, usually within the fallopian tube and
fails to develop. See Medline Plus Medical Encyclopedia, Ectopic Pregnancy, http:/www.
nlm.nih.gov/medlineplus/ency/article/000895.htm (last visited Mar. 22, 2006). In sum-
mary, it may be overly simplistic to consider fertilization as the sole prerequisite for
pregnancy to occur.
59. See Grimes, supra note 37, at 847.
60. Renee C. Wyser-Pratte, Protection of RU-486 as Contraception, Emergency
Contraception and as an Abortifacient Under the Law of Contraception, 79 OR. L. REV.
1121, 1121 (2000).
61. Id. at 1132.
62. For example, the Roman Catholic Church teaches that'life" begins at fertilization
(i.e., conception), even if "ensoulment" occurs at a later time. See Herbe, supra note 27,
at 86-87; see also THE SACRED CONGREGATION FOR THE DOCTRINE OF THE FAITH,
DECLARATION ON PROCURED ABORTION (1974), available at http://www.vatican.val
roman curia/congregations/cfaithldocuments/rc-con cfaith doc_19741118_declaration-
abortion en.html (stating the Catholic Church's stance on abortion); Hazel J. Markwell
& Barry F. Brown, Bioethics for Clinicians: 27. Catholic Bioethics, 165 CAN. MED. ASS'N
J. 189, 190 (2001).
63. See POPE PAUL VI, HUMANA VITAE, ENCYCLICAL OF POPE PAUL VI ON THE
REGULATION OF BIRTH (1968), available at http://www.vatican.va/holyfather/paul-vi/
encyclicals/documents/hfp-vi-enc_25071968_humanae-vitae-en.html (describing
contraception as unlawful and possibly a mortal sin).
64. Once a human egg and sperm fuse, the ensuing zygote has forty-six chromosomes,
the same genetic makeup as an adult human. See Stradtman, supra note 49, at 58.
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contraception is not easily resolved, and the line appears to be
arbitrarily drawn.
In the United States, two drugs have been approved for EC to
date, although only one is currently available.65 Preven® was the
first drug approved in 1998 and is a combination product containing
both an estrogen and a progestin.66 Plan B® was approved in 199967
and contains only a progestin." Interestingly, in May 2004, Barr
Pharmaceuticals, Inc., the manufacturer of Plan B®, purchased the
marketing rights to Preven® and has discontinued its sales.69 Plan
B® is a preferential product since it has a lower incidence of nausea
and vomiting than Preven® and has enhanced packaging.7" Preven®
was packaged with a pregnancy test,7' which increased its size and
cost and reaffirmed a notion that it was an abortifacient.
B. Plan B®
Plan B®, also called levonorgestrel, is a synthetic progestin
used for EC.72 Plan B® requires a prescription in this country.73
Plan B® is marketed as two doses (i.e., two tablets of 0.75 mg
levonorgestrel) which should be initiated as soon as possible
following unprotected sexual intercourse or contraceptive failure,
65. See generally CTR. FOR DRUG EVALUATION & RES., FOOD & DRUG ADMIN.,
ELECTRONIC ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC
EQUIVALENCE EVALUATIONS (2005), http://www.fda.gov/cder/ob/default.htm (containing
approval dates, patent expiration dates, and application numbers for all brand and
generic drugs approved by the FDA) [hereinafter ELECTRONIC ORANGE BOOK].
66. Id.
67. ELECTRONIC ORANGE BOOK, supra note 65, at http://www.accessdata.fda.gov/
scripts/cder/drugsatfda/index.cfm? (select "p" under "Browse by Drug Name"; then follow
"Plan B" hyperlink on page 2) (last visited Mar. 22, 2006).
68. Plan B Prescribing Information, supra note 11, at 1.
69. The Electronic Orange Book lists Preven® as discontinued. ELECTRONIC ORANGE
BOOK, supra note 65, at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.
cfm? (Select "p" under 'Browse by Drug Name"; then follow "Preven" hyperlink on page
5).
70. Carolyn Westhoff, Emergency Contraception, 349 NEW ENG. J. MED. 1830, 1832
(2003). Studies show the incidence of vomiting with Preven® is 22% compared to 8%
with Plan B®. Id. at 1831.
71. Press Release, Gyn6tics Inc., Prevenrm Emergency Contraceptive Kit-The First
and Only Emergency Contraceptive Product - Approved by the FDA (Sept. 2, 1998),
available at http://ec.princeton.edulnewslpreven.html.
72. Plan B Prescribing Information, supra note 11, at 1. The active component in
Plan B® is also widely available in combination oral birth controls such as Climara®,
Levlite®, Seasonale® and others. ELECTRONIC ORANGE BOOK, supra note 65, at
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
73. ELECTRONIC ORANGE BOOK, supra note 65, at http://www.accessdata.fda.gov/
scripts/cder/drugsatfda/index.cfm? (select "p" under "Browse by Drug Name"; then follow
"Plan B" hyperlink on page 2) (last visited Mar. 22, 2006).
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preferably within seventy-two hours.74 The first dose is followed by
a second dose, twelve hours later.7 " Plan B® is highly effective,
decreasing the risk of pregnancy by approximately 75% when used
within seventy-two hours. 76 Although EC is considered extremely
time sensitive, there is some evidence that Plan B® can be given
successfully up to 120 hours after unprotected intercourse. 7 There
are also data that both tablets can be taken in a single dose with no
loss of efficacy. 8 The main side effect of Plan B® is nausea, which
occurs in almost one quarter of patients. 79 As a result, many
practitioners recommend anti-emetic therapy with treatment.8 0
The prescribing information for Plan B® describes the mech-
anism of action as preventing ovulation or fertilization and,
alternatively, as inhibiting implantation.1 It explicitly states that
Plan B® is not effective once the process of implantation has begun,
and is not effective if the woman is already pregnant.8 2 Accordingly,
Plan B® generally is not considered an abortifacient.
C. Legal Basis
Contraception, EC, medical abortion involving drugs, 3 and
surgical abortion' are all lawful in this country.8" These practices,
however, have not always been legal. In 1873, Anthony Comstock
tried to legislate morality by introducing legislation (the Comstock
74. Plan B Prescribing Information, supra note 11, at 3.
75. Id.
76. Id. at 5.
77. Suk Wai Ngai et al., A Randomized Trial to Compare 24h Versus 12h Double Dose
Regimen of Levonorgestrel for Emergency Contraception, 20 HUM. REPROD. 307, 307, 311
(2005) (concluding that two doses of levonorgestrel are effective up to 120 hours after
intercourse).
78. Helena von Hertzen et al., Low Dose Mifepristone and Two Regimens of
Levonorgestrel for Emergency Contraception:A WHO Multicentre Randomised Trial, 360
LANCET 1803, 1803 (2002).
79. See Plan B Prescribing Information, supra note 11, at 8.
80. Ass'n of Reprod. Health Prof., Emergency Contraception - Information for
Providers of Family Planning Services, http://www.arhp.org/healthcareproviders
resources/ecresources/ecpprotocol.cfm (last visited Mar. 22, 2006).
81. See Plan B Prescribing Information, supra note 11, at 1.
82. Id.
83. Medical abortion involves administering an agent orally or by injection to induce
an abortion. T.A. Weitz et al., "Medical" and "Surgical" Abortion: Rethinking the
Modifiers, 69 CONTRACEPTION 77, 77 (2004).
84. Surgical abortion mainly involves vacuum aspiration, also referred to as suction
curettage, under local anesthesia, whereas medical abortion involves drugs such as
mifepristone, methotrexate, or misoprostol taken in combination or in sequence. Weitz
et al., supra note 83, at 78.
85. The rights to contraception and to abortion have been considered fundamental
by the Supreme Court in Griswold v. Connecticut, 381 U.S. 479, 485 (1965), and Roe V.
Wade, 410 U.S. 113, 153 (1973).
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Act) banning the mailing of obscene and immoral materials, in-
cluding contraceptive agents.8" Section 1 of the Act outlawed the sale
or distribution of "any drug or medicine, or any article whatever,
for the prevention of contraception ... ,,87 Section 2 prohibited the
mailing of "any article or thing designed or intended for the preven-
tion of contraception .... ," State variations of this law were enacted
and enforced until 1936, when the Court of Appeals for the Second
Circuit held that the use of contraception under medical supervision
is not immoral and should be excluded from Comstockery."9
Setting the stage for this decision was a general culture shift in
the early twentieth century. This shift was exemplified by Margaret
Sanger, a pioneering nurse, who advocated contraception from the
streets of Brooklyn, New York, to the steps of the United States
Supreme Court, and in the interim established the first birth control
clinic.9 °
Modern day jurisprudence involving contraception developed
from the Supreme Court decision in Griswold v. Connecticut, which
first held that women have a constitutional right to contraception.9'
This right was extended to all similarly situated persons, including
single women, in Eisenstadt v. Baird.92 In Eisenstadt, the Supreme
Court relied on the Equal Protection Clause of the Fourteenth
Amendment in recognizing a constitutional right to contraception.93
The Supreme Court later held in Carey v. Population Services
International that the right to contraception is a fundamental right,
subject to strict scrutiny, and even extends to minors, to a certain
degree.94 Furthermore, the Court held in Roe v. Wade that there is
a constitutional right to abortion95 and in Planned Parenthood v.
Casey that no state may impose an undue burden on this right.9 6
Moreover, medical abortion has been legal in the United States
86. An Act for the Suppression of Trade in, and Circulation of, Obscene Literature
and Articles of Immoral Use, ch. 258, § 2, 17 Stat. 598, 598 (1873).
87. Id. § 1.
88. Id. § 2.
89. United States v. One Package, 86 F.2d 737, 739 (2d Cir. 1936).
90. See William N. Eskridge, Jr., Some Effects of Identity-Based Social Movements
on Constitutional Law in the Twentieth Century, 100 MICH. L. REV. 2062,2118-19 (2002).
This article also discusses Sanger's birth control clinic, named the American Birth
Control League, which she founded in 1922 and was renamed the Planned Parenthood
Federation of America in 1942. Id. at 2120-21.
91. 381 U.S. 479, 485-86 (1965).
92. 405 U.S. 438, 453 (1972).
93. Id. at 443.
94. 431 U.S. 678, 693-94 (1977).
95. 410 U.S. 113, 153 (1973).
96. 505 U.S. 833, 851 (1992).
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since Mifeprex® was approved in 2000. 97 Thus, women have a
constitutionally protected right in the United States to receive
contraception and abortion without an undue burden by the state.
The issue that remains, however, is whether these rights extend to
women without a prescription. That decision, at least initially, lies
with the FDA.
98
II. REGULATION OF DRUGS
A. FDA
The FDA is an executive agency, created by Congress, whose
mission, in part, is to provide safe, effective, and properly labeled
drugs to U.S. consumers.9 In addition to regulating human drugs,
the FDA also regulates veterinary drugs,"' medical devices (e.g.,
pacemakers),0 1 radiation emitting devices (e.g., cell phones and
airport metal detectors), 10 2 cosmetics,' 3 and food, including biolog-
ical products.0 4 The responsibility of the FDA to the U.S. consumer
is enormous, and its reach is tremendous in scope, regulating over
97. Letter from the Ctr. for Drug Evaluation & Res. to Sandra P. Arnold, Population
Council (Sept. 28, 2000), available at http://www.fda.gov/cder/foi/appletter/2000/
20687appltr.htm. Also known as the French abortion pill, Mifeprex® ("RU-486") was
approved in 2000 for early abortion, defined as forty-nine days or less. See id. Mifeprexe
is dosed as three 200 mg tablets on day one under the supervision of a physician.
Mifeprex (mifepristone) Tablets Label, http://www.fda.gov/cder/foi/labelI2000/
206871bl.htm (last visited Mar. 22, 2006). On day three, if abortion has not yet occurred,
the patient takes two 200 mg tablets of CytotecS (misoprostol). Id. The patient returns
on day fourteen for a post-treatment examination. Id.
98. See 21 C.F.R. § 310.200 (2006); Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
§§ 301-397 (2005) (indicating the criteria by which the FDA decides the status of
prescription and nonprescription drugs).
99. See Food & Drug Admin., FDA's Mission Statement, http://www.fda.gov/
opacom/morechoiceslmission. html (last visited Mar. 22, 2006). The FDA's mission is to:
Protect[] the public health by assuring the safety, efficacy, and security of
human.., drugs ... [and] advancing the public health by helping to speed
innovations that make medicines and foods more effective, safer, and more
affordable; and helping the public get the accurate, science-based
information they need to use medicines and foods to improve their health.
Id.
100. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360b (2005).
101. Id. § 360c.
102. Id. §§ 360hh-360ss.
103. Id. §§ 361-363.
104. Id. §§ 341-350. The only foods not regulated by the FDA are meat, poultry, and
egg products, which are regulated by the Food Safety and Inspection Service (FSIS) of
U.S. Department of Agriculture. U.S. Dep't of Agric., About FSIS, http://www.fsis.usda.
gov/AboutFSIS/index.asp (last visited Mar. 22, 2006).
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one trillion dollars in products annually.' °5 In fact, products
regulated by the FDA account for more than twenty cents of every
dollar spent by U.S. consumers.
10 6
The FDA is one of eleven Public Health Agencies under the
Department of Health and Human Services."' The FDA has eight
centers (offices), including the Center for Drug Evaluation and
Research (CDER), which handles all matters relating to drugs
including prescription drugs.' 8 Within the CDER is the Office of
Nonprescription Products that primarily handles nonprescription
drugs.1
0 9
The Commissioner of the FDA is appointed by the President
and confirmed by the Senate."0 The President also has the author-
ity to appoint a myriad of other members to the FDA, including
advisory committee members."' The Commissioner of the FDA has
105. FOOD & DRUGADMIN., DEP'T OF HEALTH AND HUMAN SERVS., PUBL'N No. 01-1316,
THE NATION'S PREMIER CONSUMER PROTECTION AND HEALTH AGENCY (2006), available
at http://www.fda.gov/oc/opacomlbrochure/healthbro.pdf (last visited Mar. 22, 2006)
[hereinafter FDA PREMIER CONSUMER PROTECTION AND HEALTH AGENCY]. As drugs,
radiation emitting devices, and biotechnology become increasingly complex, the impact
of the FDA will become increasingly important. Interestingly, the FDA was not officially
established by statute until 1988. Food & Drug Admin., Milestones in U.S. Food and
Drug Law History, http://www.fda.gov/opacom/backgrounders/miles.html (last visited
Mar. 22, 2006). Before that time, its authority was derived from administrative and
legislative actions. Id.
106. FDA PREMIER CONSUMER PROTECTION AND HEALTH AGENCY, supra note 105. Yet
the FDA costs less than two cents per person per day to operate. Id.
107. U.S. Dep't Health & Hum. Services, About HHS, http://www.hhs.gov/about
index.html (last visited Mar. 22, 2006). The other agencies are the Administration for
Children and Families, Administration on Aging, Agency for Healthcare Research and
Quality, Agency for Toxic Substances and Disease Registry, Centers for Disease Control
and Prevention, Centers for Medicare and Medicaid Services, Health Resources and
Services Administration, Indian Health Service, National Institutes of Health, Program
Support Center, and Substance Abuse and Mental Health Services Administration. Id.
108. Food & Drug Admin., FDA Organization, http://www.fda.gov/opacom7org.html
(last visited Mar. 22, 2006). The other centers are the Center for Biologics Evaluation
and Research, Center for Devices and Radiological Health, Center for Food Safety and
Applied Nutrition, Center for Veterinary Medicine, National Center for Toxicological
Research, Office of the Commissioner, and Office of Regulatory Affairs. Id.
109. Food & Drug Admin., Ctr. for Drug Evaluation & Res., Nonprescription Products:
What We Do, http://www.fda.gov/cder/Offices/OTC/whatwedo.htm (last visited Mar. 22,
2006). The Office of Nonprescription Drug Products regulates "more than 80 classes
(therapeutic categories) of OTC drugs, ranging from acne drug products to weight control
drug products." Id. Emergency contraception is not one of these classes.
110. 21 U.S.C. § 393(d)(1) (2005).
111. Federal Advisory Committee Act, Pub. L. No. 92-463, § 1, 86 Stat. 770 (1972)
(codified at 42 U.S.C. §§ 7403 note, 7409 note, 7417 note, 7607 note, 7614 note), amended
by Pub. L. No. 94-409, 90 Stat. 1247 (1976) (codified at 5 U.S.C. §§ 552b note, 552b, 552,
554, 552a, prec. 500, 557); Pub. L. No. 96-523, 94 Stat. 3040 (1980) (codified at 5
U.S.C.§§ app., 8332, 28 U.S.C. § 640(a)(16)(A), 29 U.S.C. § 3102, 39 U.S.C. § 410(b)(1));
Pub. L. No. 97-375, 96 Stat. 1822 (1982) (codified at 33 U.S.C. § 1703); Pub. L. No. 105-
153, 111 Stat. 2689 (1997) (codified at 5 U.S.C. §§ 1 note, 3, 15, 16).
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been subject to Senate confirmation since 1988 in an attempt to give
the job more authority."2 To date, the FDA has only had four
Commissioners confirmed by the U.S. Senate.
113
The FDA has had a seemingly long and gloried history, although
it has been under increasing scrutiny following the removal of
Vioxx® 114 and ephedra" 5 in 2004, Bextra® ,' in 2005, and the Plan
B® fiasco. A closer analysis, however, shows that the political pres-
sure surrounding the FDA has been escalating for some time.
The FDA approved Mifeprex®, the French abortion pill, under
intense dispute in September 2000, the waning days of the Clinton
Administration," 7 despite numerous protests from conservative and
pro-life activists."' Immediately upon President George W. Bush's
112. Marc Kaufman, FDA's Reliance on Unconfirmed Chiefs is Faulted, WASH. POST,
Dec. 19, 2004, at Al, available at http://www.washingtonpost.com/ac2/wp-dynA10775-
2004Decl8?html.
113. Food & Drug Admin., Commissioners and Their Predecessors, http://www.
fda.gov/oc/commissioners (last visited Mar. 22, 2006). David Kessler was confirmed in
November 1990, Jane Henney was confirmed in January 1999, Mark McClellan was
confirmed in November 2002, and Lesley Crawford was confirmed in July 2005. Id. The
current acting commissioner of the FDA, Andrew C. von Eschenbach, has not yet been
confirmed by the Senate. See infra notes 129-132.
114. Vioxx®, generic name rofecoxib, is a non-steroidal anti-inflammatory, cyclo-
oxygenase 2 selective (COX-2) inhibitor used mainly for arthritis pain that was
withdrawn from the U.S. market by Merck Pharmaceuticals in 2004. Marc Kaufman,
Merck Found Liable in Vioxx Case; Texas Jury Awards Widow $253 Million, WASH.
POST, Aug. 20, 2005, at Al. Estimates are that twenty million Americans used Vioxx®
since it was first approved in 1999. Id. The drug was shown to increase the risk of heart
attack and stroke. Further estimates suggest that 89,000-139,000 Vioxx® users suffered
a heart attack or stroke, and of these approximately thirty to forty percent died. David
J. Graham, M.D., M.P.H., Testimony Bqfore the United States Senate Committee on
Finance (Nov. 18, 2004), http://fmance.senate.gov/hearings/testimony/2004test/
lll804dgtest.pdf; see also David J. Graham et al., Risk of Acute Myocardial Infarction
and Sudden Cardiac Death in Patients Treated with Cyclo-oxygenase 2 Selective and
Non-Selective Non-Steroidal Anti-Inflammatory Drugs: Nested Case-Control Study, 365
LANCET 475 passim (2005).
115. Ephedra is a dietary supplement that was removed from the market in April 2004
due to serious health risks. See FDA Statement, Food & Drug Admin., FDA Announces
Rule Prohibiting Sale of Dietary Supplements Containing Ephedrine Alkaloids Effective
April 12 (Apr. 12, 2004), available at http://www.fda.gov/bbs/topics/NEWS/2004/
NEW01050.html.
116. Bextra®, generic name valdecoxib, is a non-steroidal anti-inflammatory COX-2
inhibitor marketed by Pfizer Pharmaceuticals since 2001. Bextra® was withdrawn from
the U.S. market in April 2005 due to its risk of heart attack and life-threatening skin
reactions. FDA Alert, Food & Drug Admin., Alert for Healthcare Professionals:
Valdecoxib (Marketed as Bextra®) (Apr. 7, 2005), available at http://www.fda.gov/cder/
drug/infosheets/hcp/valdecoxibhcp.htm.
117. See Lars Noah, A Miscarriage in the Drug Approval Process?: Mifepristone
Embroils the FDA in Abortion Politics, 36 WAKE FOREST L. REV. 571, 571-72 (2001).
118. Am. Ass'n of ProLife Obstetricians & Gynecologists, AAPLOG Statement on
Mifeprex (mifepristone) and the Protection of Women's Health (Jan. 25, 2001), available
at http://www.aaplog.org/newsru486.htm.
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inauguration, Dr. Jane Henney, the Commissioner of Food and
Drugs, was fired119 and replaced with Dr. Mark McClellan, the
brother of White House Press Secretary Scott McClellan. 2 ' Although
the appointment of Dr. McClellan might have been somewhat
contentious, few people could dispute his impressive credentials,
and he was appointed by unanimous consent. 1' Dr. McClellan
served as the FDA Commissioner until March 2004, and by most
accounts did an outstanding job.'22 Dr. McClellan resigned from the
FDA in March 2004 to become the Administrator for the Centers for
Medicare and Medicaid Services.'23
In his place, President Bush appointed Dr. Lester Crawford to
head the FDA. 24 Dr. Crawford is a veterinarian with a Doctorate in
Pharmacology.'25 Dr. Crawford previously served as acting'26 and
deputy commissioner of the FDA before being appointed, and
subsequently confirmed, as commissioner.'27 Dr. Crawford's overall
tenure at the post was highly tumultuous, and he resigned suddenly
and unexpectedly amidst great controversy.'28 The current acting
commissioner of the FDA is Dr. Andrew C. von Eschenbach, the
third Bush appointee to the position.'29 Before arriving at the FDA,
Dr. von Eschenbach served as the Director of the National Cancer
Institute of the National Institutes of Health.30 Dr. von Eschenbach
119. Robert Pear, Transition in Washington: Health and Human Services: Thompson
Says He Will Order a New Review of Abortion Drug, N.Y. TIMES, Jan. 20, 2001, at A17.
120. Kaufman, supra note 112.
121. Biography - CMS Leadership, Mark B. McClellan, M.D., Ph.D., available at
http://www.cms.hhs.gov/CMSLeadership/Downloads/McClellanMarkBio.pdf (last visited
Mar. 22, 2006). Dr. McClellan earned his M.D. from Harvard and his Ph.D. in Economics
from the Massachusetts Institute of Technology. Id.
122. Id.
123. Leila Abboud, FDA Official Criticized Agency for Scrutiny of Contraceptive:
Rejected 'Plan B'Pill Faced Unique Hurdles, Reviewer's Memo Says, WALL ST. J., June
18, 2004, at B4.
124. See Food & Drug Admin., Dr. Lester M. Crawford - Biography, http://www.
fda.gov/oc/crawford/bio.html (last visited Mar. 22, 2006).
125. Id. Dr. Crawford earned his Doctor of Veterinary Medicine from Auburn
University, his Ph.D. in pharmacology from the University of Georgia, and was granted
an Honorary Doctorate (M.D.V.) from Budapest University. Id.
126. Robert Pear & Andrew Pollack, Leader of the F.D.A. Steps Down After a Short,
Turbulent Tenure, N.Y. TIMES, Sept. 24, 2005, at Al.
127. Dr. Lester M. Crawford - Biography, supra note 124. Dr. Crawford served as
Acting Commissioner from 1999-2002. Dr. Crawford has also served as the
Administrator of the Food Safety and Inspection Service of the USDA and as Deputy
Commissioner of the FDA. Id.
128. Pear & Pollack, supra note 126.
129. Nat'l Cancer Inst., U.S. Nat'l Inst. of Health, About the Director, http://www.
cancer.gov/directorscorner/about-the-director (last visited Mar. 22, 2006).
130. Id.
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has been nominated to the full time position by the President,13' but
has received strong opposition because of Plan B®, and his future
as a confirmed appointee is uncertain. 3 '
Another notable appointee to the FDA is Dr. W. David Hager,
who was appointed to serve on the FDA's Advisory Committee for
Reproductive Health Drugs. 3 3 Dr. Hager was appointed by Linda
Skladany,"' the FDA Senior Associate Commissioner in charge of
the Office of External Relations at the time. 135 The Senior Associate
position reports directly to the FDA Commissioner, 136 who is
appointed by the President. Dr. Hager was appointed as part of an
entire re-staffing in December 2002.13 Dr. Hager is considered an
eccentric physician because of his strong religious views on abor-
tion, 3 his public protests to remove Mifeprex® from the market,
and his writings on the use of prayer for the treatment of pre-
menstrual disorder.139 With the appointment of Dr. Hager, critics
perceived President Bush as stacking the FDA with conservative
cronies who obfuscate the issues surrounding EC. 4 ° Overall, the
number of recent changes and instability in the agency have
131. Press Release, The White House, Nominations Sent to the Senate (Mar. 15, 2006),
available at http://www.whitehouse.gov/news/releases/2006/03/20060315-3.html.
132. Gardiner Harris, Bush Picks FDA Chief, but Vote Is Unlikely Soon, N.Y. TIMES,
Mar. 16, 2006, at A18.
133. Marc Kaufman, Abortion Foe to be Reappointed to FDA Panel; Four Lawmakers
Tell Bush That Doctor Has Allowed His Personal Views to Overshadow His Duty, WASH.
POST, June 29, 2004, at A6.
134. See Karen Tumulty, Jesus and the FDA, TIME, Oct. 14, 2002, at 26.
135. Press Release, Food & Drug Admin., Linda Arey Skladany Appointed to Direct
FDA's Office of External Relations (July 9, 2002), available at http://www.fda.gov/
bbs/topcs/ news/2002/NEW00820.htmlI.
136. Food & Drug Admin., Organizational Chart, http://www.fda.gov/ocorgcharts/
fda.pdf (last visited Mar. 22, 2006).
137. Kaufman, supra note 133.
138. Id.
139. Published books authored or co-authored by Dr. Hager include: AS JESUS CARED
FOR WOMEN: RESTORING WOMEN THEN AND Now (1998); STRESS AND THE WOMAN'S BODY
(1996); WOMEN AT RISK: THE REAL TRUTH ABOUT SEXUALLY TRANSMITTED DISEASES
(1993).
140. Press Release, Feminist Majority Foundation, Bush Stacks FDA Panel: Ideology
Trumps Medicine and Science Again (Dec. 26, 2005), http://www.feminist.org/news/
newsbyte/uswirestory.asp?id=7384; see also Kaufman, supra note 133; Joint Committee
Report, supra note 2 passim (expressing Dr. Hager's concerns about the long-term effects
of Plan B® utilization, the contradiction of stating that Plan B® does not cause abortion
but may effect the endometrium, the unknown effect of Plan B® utilization upon younger
adolescent women, and the risk that the pricing of Plan B® will restrict access to the
drug). The Nation reports that Dr. Hager was asked to write a minority opinion for the
FDA commissioner outlining why Plan B's® application for nonprescription use be
rejected. Ayelish McGarvey, Dr. Hager's Family Values, 21 NATION 11, 18 (2005).
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clearly weakened the FDA's authority14' and complicated the issues
surrounding EC.
B. Legal Foundation
In the United States, drugs are regulated as either prescription
or nonprescription products.142 To understand the complex regula-
tory framework involving drugs, it is important to examine some of
the relevant legislation and historical milestones.
The first major law regulating drugs was the Pure Food and
Drugs Act in 1906.' This law was established to ensure the safety
and purity of food and drugs by prohibiting the "interstate com-
merce" of adulterated and misbranded products.' Accordingly,
drugs that differed from the standard on the label regarding their
strength, quality, or purity (i.e., adulterated), or drugs that were mis-
labeled (i.e., misbranded) could not be sold. 4 ' Otherwise, all drugs
could be lawfully sold, even if they were unsafe or advertised with
outlandish therapeutic claims. 4 6 In 1912, the Sherley Amendment
was passed to strengthen the Food and Drugs Act by prohibiting
false and fraudulent claims. 147 In 1914, Congress enacted the
141. See Kaufman, supra note 112.
142. See 21 C.F.R. § 310.200 (2006). Herbal remedies are considered "dietary
supplements" by the FDA and are not regulated as drugs in this country. Dietary
Supplement Health and Education Act of 1994 § 2(14), Pub. L. No. 103-417, 108 Stat.
4325-26 (1994) (codified as amended in 21 U.S.C. § 321 (2006)).
143. Pure Food and Drugs Act of 1906, ch. 3195, 34 Stat. 768 (1906) (repealed 1938).
This law was passed in response to an excessive number of cure-all claims by
unregulated and potentially dangerous products and the increasing use of harmful
preservatives and dyes. Food & Drug Admin., The Long Struggle for the 1906 Law, FDA
CONSUMER (1981), available at http://www.cfsan.fda.gov/-lrd/history2.html. Upton
Sinclair's novel, The Jungle, which publicized the unsanitary conditions of Chicago's
meatpacking plants, played a role in the establishment of this act. MARCIA ANGELL, THE
TRUTH ABOUT THE DRUG COMPANIES, 33 (2004).
144. Pure Food and Drugs Act of 1906 § 2, ch. 3195, 34 Stat. 768 (1906) (repealed
1938). Because Congress has no enumerated police powers, its authority to regulate
drugs is derived from Interstate Commerce. U.S. CONST. art I, § 8, cl. 3. As long as
legislation is rationally related to interstate commerce it will be ruled constitutional. See
Gonzales v. Raich, 125 S. Ct. 2195, 2205-06 (2005).
145. Pure Food and Drugs Act of 1906 § 2, ch. 3195, 34 Stat. 768 (1906) (repealed
1938). However, the Act did not require a manufacturer to disclose ingredients. Anny
Huang, FDA Regulation of Genetic Testing: Institutional Reluctance and Public
Guardianship, 53 FOOD & DRUG L.J. 555, 573 (1998).
146. See Huang, supra note 145, at 573.
147. Sherley Amendment, Pub. L. No. 62-301, 37 Stat. 416, 21 U.S.C. § 10 (1912)
(amended by 37 Stat. 732 (1913)). This amendment was passed in response to U.S. v.
Johnson, 221 U.S. 488 (1911), which held that the 1906 Pure Food and Drugs Act had
no regulatory authority over false claims made by drug manufacturers. Id. at 498.
Johnson Remedy Company marketed a product that knowingly made false claims of its
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Harrison Narcotic Act, requiring certain habit-forming drugs to be
sold only by licensed doctors and pharmacies, creating the first
legislative distinction between drug classes. 48
In 1937, the infamous sulfanilamide incident sparked an
important change in drug regulation.'49 Until that time, drugs did
not have to be proven safe for marketing.' ° However, in 1937, over
100 people died, many of whom were children, after ingesting an
antibiotic (sulfanilamide) dissolved in a toxic vehicle (diethylene
glycol).' 5 ' In response to that catastrophe, Congress passed the
Federal Food, Drug, and Cosmetic Act of 1938 (FDCA).' 52 This
legislation, for the first time, required that drugs be proven safe
ability to cure cancer. Id. at 494. The Supreme Court ruled Johnson was not in violation
of any law at the time because the drug was not misbranded under the current statute.
Id. at 498. In response, President Taft called on Congress to enact the Sherley
Amendment and to close this loophole. See Arthur H. Hayes, Jr., Food and Drug
Regulation After 75 Years, 246 JAMA 1223, 1223 (1981). This Amendment was not very
successful, as the government now held the burden to pursue and prove false and
fraudulent claims, a difficult task. Id.
148. Harrison Narcotic Act, Pub. L. No. 63-223, 38 Stat. 785 (1914). Interestingly,
licensure under this Act was by the Internal Revenue Bureau of the Treasury
Department. The Harrison Narcotic Act was established in response to the International
Agreement of the 1912 Hague Convention, which "Determined to bring about the
gradual suppression of the abuse of opium, morphine, and cocaine." See International
Opium Convention, January 23, 1912, http://www.cicad.oas.org/EN/treaties/mjl.htm
(last visited Mar. 22, 2006). Today all habit-forming and controlled substances are
regulated under the Controlled Substances Act (CSA), Title II of the Comprehensive
Drug Abuse Prevention and Control Act of 1970, Pub. L. No. 91-513, 84 Stat. 1236(1970)
(codified at 21 U.S.C. §§ 881-966 (2006)). For a history of drug control and enforcement
legislation, see U.S. Dep't of Justice, Drug Enforcement Admin., The Diversion of Drugs
and Chemicals, http://www.deadiversion.usdoj.gov/pubs/program/activities/background.
htm (last visited Mar. 22, 2006).
149. Prior to 1937, drugs were essentially non-regulated. As long as they were not
mislabeled or adulterated they could be marketed or sold, even if they were completely
ineffective or dangerous. See Huang, supra note 145, at 573.
150. Id.
151. See Donna Young, Documentary Examines Sulfanilamide Deaths of 1937, AM.
Soc'k HEALTH-SYS. PHARMACISTS, Dec. 5, 2003, http://www.ashp.org/news/showarticle.
cfm?id=3659. In 1937, the Massengill Company used diethylene glycol (DEG) with
raspberry flavoring to dissolve a new antibiotic (sulfanilamide) for administration to
children. Id. However, DEG is an industrial solvent and close relative to antifreeze that
can cause renal failure and death when consumed orally. Id. Amazingly enough, a
similar tragedy occurred almost sixty years later, in 1996, when eighty-five of eighty-
seven children admitted to a hospital in Haiti died after ingesting acetaminophen mixed
with DEG. See Katherine L. O'Brien et al., Epidemic of Pediatric Deaths from Acute
Renal Failure Caused by Diethylene Glycol Poisoning, 279 JAMA 1175, 1177 (1998).
152. Federal Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040
(1938) (codified as amended at 21 U.S.C. § 321 (2006)). The Food Drug and Cosmetic Act
was signed by President Franklin D. Roosevelt on June 25, 1938 and completely
revamped the 1906 Pure Food and Drug Act. See Thomas F. McGuire, Food, Drug or
Both? Dual Classification Under the Federal Food, Drug, and Cosmetic Act, 1984 U. ILL.
L. REv. 987, 992-93 (1984).
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before marketing.153 In addition, it established the requirement of
a New Drug Application (NDA) for each drug prior to entry into
interstate commerce.' It also expanded previous drug-labeling
requirements, authorized factory inspections of drug manufacturers,
and added the remedy of court injunctions to the established
penalties of seizures and prosecutions.'55 This act is the basis of our
current drug laws.
The distinction between prescription and non-prescription
drugs was formally established in 1951 when Congress enacted the
Prescription Drug Amendments to the FDCA, also know as the
Durham Humphrey Amendments." 6 The purpose of this legislation
was to mandate certain drugs be used only under the supervision of
a physician,"' creatinga separation of prescription and nonprescrip-
tion drug classes. Under this law, any drug with the potential for
addiction, or unsafe for use except under supervision, or applied for
under a prescription drug application, requires a prescription.'58 All
other drugs are considered nonprescription. Thus, the Durham
Humphrey Amendments establish a bright-line rule for differentiat-
ing prescription and nonprescription drugs.5 9 Prior to this act, drug
manufacturers were allowed to determine by which means they
would market their products, whereas now the FDA makes this
153. See McGuire, supra note 152, at 993. Prior to the enactment of the Food, Drug,
and Cosmetic Act, drugs were not required to undergo any testing or proof of safety. See
Huang, supra note 145.
154. 21 U.S.C. § 355(a) (2006).
155. John P. Swan, History of the FDA, in THE HISTORICAL GUIDE TO AMERICAN
GOVERNMENT (George Kurian ed., 1998), available at http://www.fda.gov/oc/history/
historyoffda/fulltext.html. This new court remedy was necessary for the FDA to
accomplish its new responsibilities. See Kepten D. Carmichael, Strict Criminal Liability
for Environmental Violations: A Need for Judicial Restraint, 71 IND. L.J. 729, 738 n.62
(1996).
156. Durham-Humphrey Drug Prescriptions Act, Pub. L. No. 82-215, 65 Stat. 648
(1951) (codified as amended in scattered sections of 21 U.S.C.). These amendments were
named after Democratic Senator Hubert Humphrey from Minnesota, who was later Vice
President to Lyndon B. Johnson, and Democratic Congressman Carl Durham from North
Carolina, both pharmacists.
157. Id. 21 U.S.C. §§ 321, 331-32, 348, 351-3, 355, 357-60, 372, 374, 381 (2005).
158. Id. The original requirement of a prescription for all potentially addictive drugs,
21 U.S.C. § 352 d), was repealed by Pub. L. No. 105-115 on Nov. 21, 1997. See also Lori
R. Jacobs, Prescription-to-over the Counter Drug Reclassification, 57 AM. FAM. PHYSICIAN
2209, 2209 (1998).
159. Under the Durham Humphrey Amendments, drugs that can be used safely and
effectively without requiring the supervision of a physician will be regulated as non-
prescription. Drugs that require the supervision of a physician, or are used to treat a
condition that requires the care of a physician, will be prescription-only. See Jacobs,
supra note 158, at 2209.
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determination. 6 ' Table 1 includes a list of criteria used by the FDA
to decide the suitability of a drug for nonprescription use. 6'
Following the enactment of the Durham Humphrey Amendments,
drug regulation in this country remained static162 until the thalido-
mide tragedy. In 1961, a number of worldwide reports found horrific
fetal abnormalities in children born to mothers who took thali-
domide." Although the drug was not approved for use in this
country,"M in reverberation" Congress passed the 1962 Kefauver
Harris Drug Reform Amendments to the 1938 Food, Drug, and
Cosmetic Act." This law gave the FDA increased authority in its
decision making power"' and has since set it among the most
reputable regulatory agencies in the world." An important inclusion
in this act was the requirement that drugs be proven safe and
effective by "substantial evidence" before they could be marketed in
this country.'69 The act also established and required compliance with
"current good manufacturing practice" to better protect consumers.17
0
Thus, prior to 1938, drugs required no proof of safety' 7' and,
prior to 1962, needed no proof of efficacy before marketing. Accord-
ingly, after these amendments, there were a large number of drugs
on the market in violation of the current law. Drugs marketed
before 1938 were never proven safe or effective. Drugs approved
between 1938 and 1962 were proven safe, but not effective. In
response to these limitations, the FDA "grandfathered" all pre-1938
drugs, allowing them to remain on the market, and required certain
procedures to evaluate drugs approved between 1938 and 1962 for
160. See Stan Stringer, What Has Been Happening with over the Counter Drug
Regulation, 53 FOOD & DRUG L.J. 633 passim (1998).
161. See infra tbl.1. Note that the FDA has never formally published these criteria and
the precise influence of each factor in the decision-making process is uncertain. The FDA
likely considers the totality of the circumstances when considering whether a drug is
suitable for nonprescription use instead of any rigid mathematical formula.
162. During the period between 1951 and 1961, not a single major federal drug law
was enacted.
163. See supra note 3 and accompanying text.
164. See Keffer, supra note 3, at 93, 96.
165. See Mary T. Griffin, AIDS Drugs & the Pharmaceutical Industry: A Need for
Reform, 17 AM. J.L. & MED. 363, 377 (1991).
166. Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (1962) (codified as
amended at 21 U.S.C. §§ 321, 331-2, 348, 351-3, 357-60, 372, 374, 381). See also Jacobs,
supra note 158, at 2209.
167. Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (1962) (codified as
amended at 21 U.S.C. §§ 321, 331-2, 348, 351-3, 357-60, 372, 374, 381).
168. Griffin, supra note 165, at 375.
169. Id. § 102 (codified at 21 U.S.C. § 355(d) (2005)).
170. Id. § 101 (codified at 21 U.S.C. § 360(f) (2005)).
171. See McGuire, supra note 152, at 993.
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their efficacy.'72 These procedures included having the National
Research Council of the National Academy of Sciences evaluate the
drugs and remove the drugs lacking evidence of efficacy through the
Drug Efficacy Study Implementation (DESI) review program.'73 The
procedures also included the 1972 Over-the-Counter Drug Review
for nonprescription drugs.174 All nonprescription drugs available
today are subject to approval under a New Drug Application (NDA)
or a monograph recognizing the drug as generally safe and effective
before marketing.
175
C. Rx to OTC Switch
A drug approved as requiring a prescription can "switch" to
over-the-counter status by submitting a supplemental New Drug
Application (sNDA) and demonstrating it meets one of the excep-
tions to the Durham Humphrey Amendments or "such requirements
[of prescription-only status that] are not necessary for the protection
of the public health."'76 This switch may be initiated by the FDA,
the drug manufacturer, or any interested person through a citizen's
petition. 17
In the United States, there is an increasing trend toward Rx to
OTC switches. It is estimated that in the past thirty years, more than
700 drug products have made the transition.17 It is almost nostalgic
to consider products such as Children's Motrin®, hydrocortisone
cream, nicotine patches, and Rogaine® as drugs once requiring a
172. See Stringer, supra note 160, at 633. The Drug Efficacy Study Implementation
(DESI) review program called for the National Research Council of the National
Academy of Sciences to evaluate more than 16,000 claims for approximately 4000 drugs
approved between 1938 and 1962 for efficacy. Joseph L. Fink, III, Jesse C. Vivian & Kim
K. Reid, Facts and Comparisons, PHARMACY LAW DIGEST 33 (37th ed. 2003) (1965)
[hereinafter PHARMACY LAW DIGEST]. The review program established eighty-six drug
categories, performed reviews, accepted public comments, and issued final monographs.
Id. During this review period all drugs were permitted to remain on the market. See
Stringer, supra note 160, at 635-36. The review, which has taken more than 40 years to
complete, found "14.7% of the drugs ineffective, 34.9% possibly effective, 7.3% probably
effective, 19.1% effective and 24% to be effective, but . PHARMACY LAW DIGEST,
supra, at 33.
173. PHARMACY LAw DIGEST, supra note 172, at 33.
174. See Robert G. Pinco, Implications of FDA's Proposal to Include Foreign Marketing
Experience in the Over-the-Counter Drug Review Process, 53 FOOD & DRUG L.J. 105, 105
(1998).
175. Id. at 106; see 21 C.F.R. § 330.10 (providing procedures "for classifying drugs as
generally recognized as safe and effective, and not misbranded, and for establishing
monographs").
176. 21 U.S.C. § 353(b)(3) (2005).
177. Grimes et al., supra note 40, at 154.
178. Grimes, supra note 37, at 846.
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prescription. 79 Most recently, Prilosec®'8 ° and Claritin®'s' have
been reclassified as nonprescription products, demonstrating a
growing acceptance by the FDA that certain drugs can be safely
used without the supervision of a physician.
The mounting trend toward nonprescription use of prescription
drugs mostly is motivated by financial concerns. 18 2 For example, the
nonsedating antihistamine, Claritin®, was recently available by
prescription only, despite strong protests from consumer protection
groups and insurance companies."8 However, once Claritin® came
off patent, the manufacturer determined the drug would be more
profitable if available without a prescription and applied for, and
received, nonprescription status.M Nevertheless, the importance of
this issue for EC is unique. The demand for nonprescription access
to EC is driven by social and political, rather than financial,
concerns.
III. PLAN B® FOR NONPRESCRIPTION USE
A. FDA Evaluation
The FDA approved Plan B® as a prescription drug on July 28,
1999, pursuant to an NDA. 88 Plan B® was deemed safe and
179. Other common drugs that have undergone Rx to OTC switch since 1990 include
Gyne-Lotrimin® for vaginal yeast infections; IvyBlock® for Poison Ivy protection;
Monistat 7® for vaginal yeast infections; Aleve® for pain, fever, and inflammation;
Pepcid AC® for acid reflux disease; and Lamisil AT® for Athlete's Foot. CONSUMER
HEALTHCARE PRODUCTS ASS'N, INGREDIENTS & DOSAGES TRANSFERRED FROM Rx-TO-OTC
STATUS (OR NEW OTC APPROVALS) BY THE FOOD AND DRUG ADMINISTRATION SINCE 1975
(Jan. 26, 2006), available at http://www.chpa-info.org/web/advocacy/general-issues
switch/switchjlist.pdf.
180. See Food & Drug Admin., Drug Information: Questions and Answers on Prilosec
OTC (omperazole), http://www.fda.gov/cder/drug/infopage/prilosecOTC/prilosecotcQ&A.
htm (last visited Mar. 22, 2006).
181. Updates: FDA Approves OTC Claritin, 37 FDA CONSUMER 3, 3 (Jan.-Feb. 2003),
available at http://www.fda.gov/fdac/departs/2003/103-jupd.htm.
182. See Holly M. Spencer, Note, The Rx-to-OTC Switch of Claritin, Allegra, and
Zyrtec: An Unprecedented FDA Response to Petitioners and the Protection of Public
Health, 51 AM. U. L. REV. 999, 1001-02 (2002).
183. See ANGELL, supra note 143, at 186-87.
184. Id. at 187. The original patent on Claritin was due to expire in 1998, id. at 186;
however, after extensive maneuvering by its manufacturer, Schering-Plough, and an
estimated $5 million in legal costs, the patent was extended through 2002. Id. at 186-87.
185. See Joint Committee Report, supra note 2, at 20, 21. During the drug approval
process, the FDA can issue an "Approval" letter, a "Not Approvable" letter, or an
"Approvable" letter. See Food & Drug Admin., Ctr. for Drug Evaluation & Research,
CDER Data Standards Manual, http://origin.www.fda.gov/cder/dsm/GEN/genl0306.htm
(last visited Mar. 22, 2006). Approved drugs have met all statutory requirements and are
considered safe and effective for their intended use and can be sold and marketed in this
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effective for the prevention of pregnancy in women of all reproduc-
tive ages. 1 6 On February 14, 2001, a citizens' petition was filed by
the Center for Reproductive Law and Policy on behalf of sixty-six
organizations requesting the availability of EC without a prescrip-
tion.'87 The petition asserted that EC met all of the regulatory
requirements for nonprescription use and should be available
without a prescription. 8 However, the petition was not formally
decided by the FDA at that time. 89
On April 16, 2003, Women's Capital Corporation (WCC), now
Barr Pharmaceuticals, Inc., submitted a sNDA to the FDA to
market Plan B® without a prescription based on its ability to be
used appropriately without the supervision of a physician. 9 ° The
application contained extensive support including clinical and
behavioral data, label comprehension information, proof of actual
use, and safety information.'
91
This labeling comprehension study was designed to assess
understanding of various aspects of a prototype label such as
indications, contraindications, dosing, possible side effects, and
country. Food & Drug Admin., Ctr. for Drug Evaluation & Res., New Drug Application
(NDA) Process, http://www.fda.gov/cder/regulatory/applications/nda.htm (last visited
Mar. 22, 2006). Not Approvable drugs fail to meet such requirements and are not
permitted for sale or marketing. Id. Approvable drugs have substantially met
requirements for approval but must submit additional data in areas of deficiency before
they can be sold and marketed. Id.
186. See Plan B Prescribing Information, supra note 11. Note that the product labeling
does not include any age restrictions, suggesting that Plan B® has been deemed by the
FDA as safe and effective for woman of all reproductive ages.
187. See Letter from the Ctr. for Reprod. Law & Pol'y, Citizen's Petition to FDA (Feb.
14, 2001), available at http://www.fda.gov/ohrms/dockets/dailys/O1/FebO1/021401/
cp00001.pdf.
188. Id. at 3-4. The petition claimed that EC is safe and effective for self-medication,
its labeling is tailored to self-administration, and it is used to treat a condition which is
self-diagnosable. Id. at 3.
189. See Press Release, Ctr. for Repro. Rights, Center Sues FDA for Denying Women
Over-the-Counter Access to Emergency Contraception (Jan. 21, 2005), available at
http://www.crlp.org/pr_05_0121planb.html. The Center for Reproductive Law and Policy
filed suit against the FDA for its failure to act. Id.
190. See GAO UNUSUAL DECISION REPORT, supra note 1, at 42; see also Joint
Committee Report, supra note 2. The application involved the CARE (Convenient Access,
Responsible Education) Program. See Newsletter, FDA Advisory Comm., Barr Plan B
Emergency Contraceptive OTC CARE Program Adequate, Cmte. Says (Dec. 16, 2003) (on
file with author). CARE is designed to enhance the safe use of Plan B® without a
prescription. See Joint Committee Report, supra note 2, at 69-70. The four "core"
elements of the CARE program include a consumer toll-free hotline staffed by healthcare
professionals, an educational program with distribution of published materials, limited
distribution of the product only to retail operations with pharmacy. services or clinics,
and a system to monitor and update the program accordingly. Id. at 73-77.
191. Joint Committee Report, supra note 2, at 39-56.
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management of serious complications.'92 Patients were recruited at
shopping malls and family planning clinics in eight U.S. states. 193
The study found that 93% of women recognized proper indications
and 97% understood initiation of the product must be within seventy-
two hours.' Additionally, 98% of women understood not to use the
product if they were already pregnant and 94% recognized that the
drug does not prevent HIV or AIDS.'95
The actual use study was designed to evaluate anticipated use
under simulated over-the-counter conditions. 196 The investigators of
this study followed up with patients one and four weeks after
providing them with EC. 19 7 The study evaluated the patients' self-
selection and timing of doses. 9' The results showed that all of the
reasons given for using EC were consistent with the labeled
indication for use with 95% taking the first dose within seventy-two
hours as directed, and 74% taking the second dose exactly twelve
hours later (93% took the second pill within sixteen hours after the
first pill), indicating that "women do not need provider intervention
to use the levonorgestrel regimen of emergency contraception pills
safely and effectively." 9 9 Overall, it appears that the application
(sNDA) met all of the requirements for the switch.
As a routine part of the drug approval process, relevant indepen-
dent FDA advisory committees met to discuss the application and
make a recommendation to the deciding body.200 On December 16,
2003, a joint panel of the FDA's Reproductive Health Drugs Advisory
Committee and Nonprescription Drugs Advisory Committee voted
twenty-three to four to recommend approval of Plan B® without a
prescription." 1 The panel found the drug safe for use without a
192. Elizabeth G. Raymond et al., Comprehension of a Prototype Over-the-Counter
Label for an Emergency Contraceptive Pill Product, 100 OBSTETRICS & GYNECOLOGY 342,
342 (2002).
193. Id. at 342-43.
194. Id. at 346 tbl.3.
195. Id.
196. Elizabeth G. Raymond et al., 'Actual Use" Study of Emergency Contraceptive Pills
Provided in a Simulated Over-the-Counter Manner, 102 OBSTETRICS & GYNECOLOGY 17
passim (2003).
197. Id. at 18.
198. Id. at 17-18.
199. Id. at 23. The predominant reasons that patients provided for using EC were that
a condom broke (45%) or that the intercourse was unprotected (40%). Id. at 20.
200. See Joint Committee Report, supra note 2. Advisory committees have been
required under the Federal Advisory Committee Act since 1972. For the FDA's
provisions concerning "Public Hearing Before a Public Advisory Committee," see 21
C.F.R. §§ 14.1-14.174 (2006).
201. See Joint Committee Report, supra note 2, at 395.
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prescription with no reports of death or cardiovascular events. °2
Furthermore, the potential for misuse and abuse was minimal and
the risk of ectopic pregnancy was low. 20 The only concerns noted were
from a small minority of members and involved the low number of
young adolescents included in the studies, 20 4 as the application con-
tained data on only twenty-nine patients aged fourteen to sixteen
and no data on patients under age fourteen.05
In response to these concerns, on March 11, 2004, Barr amend-
ed their application proposing Plan B® without a prescription for
women sixteen years of age and older, while requiring a prescription
for women under sixteen years of age.20 6 As part of this proviso, Barr
outlined the CARE program to address many of the concerns
noted.20 7 Although the advisory committee had already shown
overwhelming support for Plan B® nonprescription use, Barr
wanted to assure a favorable decision.0 8
B. FDA Decision
In an unexpected turn of events, on May 6,2004, the FDA issued
a "Non-Approvable" letter to Barr, signed by the Director of the
CDER.2°" The FDA deemed the application incomplete and inade-
quate for a full review, citing the lack of data that Plan B® could be
"used safely by young adolescent women ... without the professional
supervision of a [physician]."2 10 Moreover, the FDA expressed
concerns regarding how Barr would comply with both the prescrip-
tion and nonprescription requirements in the same packaging.
211
202. Id. at 344-45, 349.
203. Daniel Davis, Medical Officer Safety Review (Nov. 15, 2003), at 4,
http://www.fda.gov/ohrms/dockets/ac/O3/briefing/4015Bl _12 FDA-Tab%205-1-
Medical%200fficer%20Review.doc (reviewing the safety of Plan B®).
204. See Joint Committee Report, supra note 2, at 354-57.
205. See Letter from Steven Galson, Acting Dir., Ctr. for Drug Evaluation & Research,
to Joseph A. Carrado, Senior Dir., Regulatory Affairs, Barr Research Inc. (May 6, 2004),
Plan B NA letter NDA 21-045/S-011, available at http://www.fda.gov/cder/drug/
infopage/planB/planBNALetter.pdf [hereinafter Plan B Letter].
206. Id. The FDA was unable to complete a full review of this amendment because it
was "preliminary and incomplete." Id.
207. See supra note 190 and accompanying text.
208. Joint Committee Report, supra note 2.
209. Id. The Director of the CDER does not usually sign decision letters. Gardiner
Harris, Morning-After Pill Ruling Defies Norm, N.Y. TIMES, May 8, 2004, at A13.
However, Dr. Steven Galson, the Acting Director, chose to sign this letter because his
opinion differed from that of the review staff on the adequacy of data in young
adolescents. Id. He believed that additional data were needed. Id.
210. Plan B Letter, supra note 205.
211. Id.
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The FDA letter provided instructions for Barr to follow before
its application could be approved.212 Ironically, in the same response
letter, the FDA conceded that the "[w]ide availability of safe and
effective contraceptives is important to public health."21 Critics
were quick to characterize the FDA's decision as political because of
the overwhelming support by the advisory committee and the
extensive data submitted. 14 Although the FDA is not required to
follow advisory recommendations, there is usually sufficient logic
and reasoning to do so.215
In response to this rejection, on July 22, 2004, Barr submitted
data to the FDA, which had six months to make another decision.1 6
Barr developed an innovative approach to the FDA's recommenda-
tions and proposed bifurcated, single package labeling, allowing
Plan B® to be sold with and without a prescription in the same
packaging. 2 7 Nevertheless, on January 21, 2005, as the six-month
deadline passed, the FDA announced a delay, citing their inability
to complete the review in time.21 Once again, this decision outraged
many people and was seen as filibustering by the FDA.219 Ironically,
this announcement came one day after President Bush's second
inauguration.220
212. Id. The FDA recommended that Barr supply additional evidence that Plan B®
could be used safely for women under age sixteen or that it could be packaged for both
prescription and nonprescription use while meeting the necessary legal requirements.
Id.
213. Id.
214. See Marc Kaufman, Staff Scientists Reject FDA's Plan B Reasoning, WASH. POST,
June 18, 2005, at A02. Top agency reviewers at three different levels in the FDA
dismissed Dr. Galson's reasoning for refusing to accept Barr's Application. Id.
215. It is believed that this is only the second time in the last five decades that the
FDA has refused to follow the advisory committee's recommendation. See Senator
Hillary Rodham Clinton, Floor Statement (As Prepared), The Bush Administration's
Repeated Attempts to Put Politics and Ideology over Science (June 15, 2005), available
at http://clinton.senate.gov/-clinton/speeches/2005616647.html.
216. See Press Release, Barr Pharmaceuticals, Inc., Barr Submits Response to FDA
in Support of Over-the-Counter Status for Plan B® Emergency Contraceptive (July 22,
2004), available at http://www.barrlabs.comlpages/nprpr.html [hereinafter Barr
Response]. According to the Prescription Drug User Fee Act, the FDA must make
regulatory decisions such as this within six months. Prescription Drug User Fee Act of
1992 § 106(c), Pub. L. No. 102-571, 106 Stat. 4491 (1992) (codified at 21 U.S.C. §§ 301
note, 379g note, prec. 379g, 379g, 379h); see also Press Release, Barr Pharmaceuticals,
Inc., FDA Decision on Plan B® OTC Status Delayed (Jan. 21, 2005), available at
http://ec.princeton.edu/news/PlanB-OTC.html [hereinafter Plan B Status Delayed].
217. See Barr Response, supra note 216.
218. See Plan B Status Delayed, supra note 216.
219. See Press Release, Ctr. for Repro. Rights, supra note 189.
220. U.S. Dep't of State, President Bush Inauguration http://usinfo.state.gov/speciall
inauguration.html (last visited Mar. 22, 2006).
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This delay also triggered a threatened block of Dr. Crawford's
confirmation hearings by prominent Democratic Senate Committee
embers until a decision was made by the FDA.22' In response to
escalating fears that Dr. Crawford would not be confirmed, Michael
Leavitt, the Secretary of Health and Human Services, wrote a letter
to Senator Michael Enzi, the Chairman of the Committee on Health,
Education, Labor and Pensions, asserting that he had spoken with
the FDA and that a decision would be made by September 1, 2005.222
Assured of an action date, the senators lifted their block and, on
July 18, 2005, Dr. Crawford was confirmed by a vote of seventy-
eight to sixteen, with six members not voting.223
Then, on Friday, August 26, 2005, as Hurricane Katrina224 had
ripped across South Florida and was approaching New Orleans, the
FDA announced a further delay.225 This time, the FDA expressed
uncertainty of whether or not the same active ingredient "may be
simultaneously marketed in both a prescription drug product and
an OTC drug product," 226 although a number of currently marketed
products had previously been approved under this system.227
221. Gardiner Harris, 3 Senators Plan to Bar Vote on F.D.A. Head, N.Y. TIMES, June
10, 2005, at A13.
222. Letter from Michael 0. Leavitz, Sec'y of Health & Hum. Services, to Michael
Enzi, Chairman, Comm. on Health, Educ., Labor & Pensions (July 13, 2005), available
at http://murray.senate.gov/healthcare/HHS-letter.pdf.
223. U.S. Senate, Vote Summary on the Nomination (Confirmation Lester M.
Crawford, of Maryland, to Be Commissioner of Food and Drugs), available at
http://www.senate.gov/legislative/LIS/roll-call_lists/roll-call-vote-cfm.cfm?congress=
109&session=l&vote=00190#top.
224. Hurricane Katrina is believed to be the costliest hurricane in history with total
losses estimated at $140 billion. See After the Hurricanes: Impact on the Fiscal Year 2007
Budget: Hearing Before the H. Budget Comm., 109th Cong. (2005) (statement of Douglas
Holtz-Eakin, Dir. Of the Cong. Budget Office), available at http://www.cbo.gov/ftpdocs/
66xx/doc6684/10-06-Hurricanes.pdf.
225. Letter from Lester M. Crawford, Comm'r of Food & Drugs, Food & Drug Admin.,
to Joseph A. Carrado, Senior Dir., Regulatory Affairs, Duramed Research, Inc., NDA 21-
045/S-0 11, available at http://www.fda.gov/bbs/topics/newsl2005/duramed_ltr. html (last
visited Mar. 16, 2006) [hereinafter Sponsor Letter].
226. Id.
227. Drug Approvals: Circumstances Under Which an Active Ingredient May Be
Simultaneously Marketed in Both a Prescription Drug Product and an Over-the-Counter
Drug Product, 70 Fed. Reg. 52050 (proposed Sept. 1, 2005) (to be codified at 40 C.F.R. pt.
310) [hereinafter Drug Approvals]. The FDA has "allow[ed] marketing of the same active
ingredient in products that are both prescription and OTC, assuming some meaningful
difference exists between the two that makes the prescription product safe only under
the supervision of a licensed practitioner." Id. Examples of drugs simultaneously
marketed as both prescription (Rx) and nonprescription (OTC) products include
Meclizine (Rx for vertigo, OTC for motion sickness), Clotrimazole (Rx for candidiasis,
OTC for athlete's foot), Loperamide (Rx for chronic diarrhea, OTC for acute diarrhea),
nicotine products (Rx for inhaler, OTC for gums and patches), and Ibuprofen (Rx for >
400 mg for arthritis, OTC for < 400 mg for aches and pains). Id.
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Interestingly, the FDA did concede that Plan B® is safe and
effective for women seventeen years of age and older and could be
available without a prescription in those patients; however, their
current decision was to the contrary.228
The FDA also issued an advance notice of proposed rulemaking,
requesting a sixty-day public comment period on the issue of
simultaneous marketing ending November 1, 2005.229 The FDA did
not commit to any timetable for ruling on this matter and many
critics viewed this act as simply another stall technique.3 ° In fact,
on March 9, 2006, Congressman Waxman wrote a letter to the
FDA's Acting Commissioner describing a number of "undisclosed
documents" that raised this same regulatory issue at least fifteen
months prior to the delay.21' Although the question at hand is valid,
and the FDA's concerns are relevant, the manner in which these
concerns have been raised undermined the FDA's credibility. Now
the FDA is left to mull over some 10,000 responses that have been
received and still must establish a clear course of action,3 2 some-
thing the FDA has been unable to accomplish to date.
The FDA's inability to resolve this matter is a clear breach of
the promise that government health executives made to U.S.
Senators and has caused political backlash. First, the Assistant
Commissioner for Women's Health and Director of the Office of
Women's Health at the FDA, Dr. Susan Wood, promptly resigned
from office, citing the agency's complete disregard for science and
harmful actions towards women's health.233 Then, the Commissioner
of Food and Drugs, Dr. Lester Crawford, suddenly and mysteriously
resigned, with no public explanation whatsoever, just sixty days
after being confirmed.234
Proponents of the FDA's decision not to approve Plan B® for
nonprescription use to date declare rectitude in public welfare and
the protection of our youth by elected officials. 235 They cite a letter
to President Bush, signed in January 2004 by forty-nine conserva-
tive members of Congress, requesting the rejection of the Plan B®
228. See Sponsor Letter, supra note 225.
229. See Drug Approvals, supra note 227.
230. See John J. Lumpkin, FDA Passed on Morning-After Pill, CBS NEWS.CoM, Nov. 1,
2005, http://www.cbsnews.com/stories/2005/11/01/health/mainlOO1547.shtml.
231. See Letter of Representative Henry Waxman to the FDA (Mar. 9,2006), available
at http://www.democrats.reform.house.gov/Documents/20060309124932-06797.pdf.
232. Marc Kaufman, FDA Comment Period on 'Morning-After Pill'Ends, WASH. POST,
Nov. 2, 2005, at A14.
233. Susan F. Wood, Women's Health and the FDA, 353 NEw ENG. J. MED. 1650, 1650
(2005).
234. See Pear & Pollack, supra note 126.
235. See Grimes, supra note 37, at 847-48.
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application.236 Opponents of the FDA's decision fear a slippery slope.
They view the decision as election year politics by an executive
agency plagued with a conservative agenda.237 More importantly,
they fear a growing public health crisis in this country involving
unintended pregnancy.
238
Following the initial refusal to approve Plan B® without a
prescription, Senator Clinton from New York wrote a letter, co-
signed by twenty-three other senators, requesting a Senate
investigation and a Government Accountability Office inquiry into
the inconsistencies of the FDA's decision.2 39 The GAO released the
requested report in November 2005, which contained a number of
"unusual" findings. 240 The report concluded that the Plan B®
application was handled differently from other applications because
it was the first time the FDA went against an advisory recommen-
dation; it was signed by an FDA official who does not normally sign
such letters; high-level FDA management was particularly involved
in the decision; the FDA gave conflicting accounts on why the
application was rejected; and the rationale for rejecting the ap-
plication was novel and varied.24'
It seems clear that the battle to approve Plan B® is predom-
inantly political and minimally scientific. It is important to
remember that Congress funds the FDA,242 the President appoints
the Commissioner, and the current administration and legislature
are conservative. A further analysis of the situation illustrates more
subtle and pressing issues. For example, there may be certain
practical considerations for approving a drug without a prescription
for one age group and requiring a prescription for another age
group. 243 For instance, this distinction creates the need to define
236. See Kaufman, supra note 214.
237. Jill Wechsler, Politics Versus Science in Biomedical Research and Development:
Decisions to Accelerate the Approval of AIDS Combination Drugs, Reject Over-the-
Counter Status for the Morning After Pill, and Limit Support for Stem Cell Research
Reflect Mounting Political Pressures, 28 PHARMACEUTICAL TECH. 24, 24 (2004).
238. See, e.g., Grimes, supra note 5, at 221.
239. See Kaufman, supra note 214; see also Press Release, Senator Hillary Rodham
Clinton, Colleagues Call for "Plan B" Probe (June 16, 2004), available at
http://clinton.senate.gov/-cinton/news/2004/2004618858.html.
240. GAO UNUSUAL REPORT, supra note 1.
241. Id. at 5-7.
242. The FDA's proposed budget for 2006 is approximately $1.9 billion. Press Release,
Lester M. Crawford, Acting Comm'r, Food & Drug Admin., Message from the Acting
Commissioner (Feb. 9, 2005), available at http://www.fda.gov/oc/oms/ofm/budget/2006/
commissioner. htm.
243. The proposed application for Plan B® requires a prescription for women under
the age of sixteen, but not for women sixteen years of age and older. See Plan B Letter,
supra note 205. It would be very easy to circumvent this prescription requirement for
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acceptable identification for proof of age.244 This would also create
financial consequences because insurance plans do not cover non-
prescription drugs, including EC, as part of their routine practice.24
There may be the social consequences to increasing access to EC.246
These issues are of great relevance and are not easily addressed.
The possible advantages to having EC available without a
prescription include increased awareness of the product, improved
access to the product, a decrease in unwanted pregnancies, a
decrease in abortions,24 ' and provision of an important option for
victims of sexual assault.248 Possible disadvantages include promo-
tion of promiscuous and unprotected intercourse, spread of sexually
transmitted diseases, fear of excessive and inappropriate use, and
erosion of our overall respect for life.249 Both sides have compelling
arguments; however, suffice it to say, they are nonscientific
arguments.
C. Statewide Protocols and Collaborative Agreements
Although EC currently requires a prescription from a physician
in this country, eight states - Alaska, California, Hawaii, Maine,
Massachusetts, New Hampshire, New Mexico, and Washington -
have passed laws bypassing this requirement by allowing pharma-
cists to dispense EC without a prescription under statewide
protocols and collaborative practice agreements.25 ° New York
received initial approval from the State Assembly to make EC
available without a prescription, but the bill was vetoed by the
most women less than sixteen years of age by simply asking a relative or friend to make
the purchase.
244. Many people do not have state-issued photo identification and this may cause
problems for pharmacists. EC is very time sensitive and the pharmacist may be
reluctant to deny sales to women for such an important drug in cases without proper age
identification. Also, issues of "proper" identification and fake identification will force
pharmacists into policing roles and away from counseling roles.
245. If Plan B® becomes available without a prescription, consumers will have to bear
the cost directly as insurance will not cover it. See Spencer, supra note 182, at 1001-02;
see also Lance W. Rook, Listening to Zantac: The Role of Non-Prescription Drugs in
Health Care Reform and the Federal Tax System, 62 TENN. L. REV. 107, 109 (1994).
246. Many believe that increasing access to EC will have negative social consequences
because young women will have a diminished valuation of pregnancy and intercourse.
See Grimes, supra note 37, at 847. Others see increased access as a necessity to protect
against unwanted pregnancy and ensure free choice. Id.
247. See, e.g., id. at 846-48.
248. Yuliya F. Schaper, Emergency Contraception for Rape Victims: A New Face of the
Old Battleground of Legal Issues in the Bi-Partisan Abortion Politics in the United
States, 29 RUTGERs L. REC. 1, 15-16 (2005).
249. See, e.g., Grimes, supra note 37, at 846-47.
250. See Raine et al., supra note 7, at 54; see also Grimes, supra note 5, at 221.
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Governor.2"' In brief, these protocols allow pharmacists with
approved training who work with an "authorized prescriber" (i.e.,
physician), to prescribe and dispense EC without a prescription.252
A total of sixteen states have either passed, attempted to pass, or
are in the process of proposing legislation to provide EC through
pharmacists without a prescription.25
It appears, therefore, that a number of states are undermining
the regulations of the Food Drug and Cosmetic Act by enacting
legislation to provide EC without a prescription while other states
are lagging behind. This disparity may lead to Equal Protection,
Equal Rights, and Equal Privileges arguments between citizens of
different states.5 4 The legal and political ramifications of these
statewide protocols and collaborative practice agreements have not
been fully elucidated, and their future remains clouded. Still, a
better solution may be readily available: the establishment of a
pharmacist-only class of drugs.2 5
IV. PHARMACIST-ONLY DRUG REGULATION
In the United States, drugs are classified either as "legend
only," which requires a medical prescription, or available without a
251. Al Baker, Pataki Vetoes Bill That Would Ease the Availability of the Morning-
After Pill, N.Y. TIMES, Aug. 5, 2005, at B3.
252. See Field, supra note 7, at 159-61 (describing in detail the dependent pharmacist
prescribing model).
253. The Pharmacy Access Partnership was established in 1999 to promote knowledge
about contraceptives among pharmacists. Their website provides a current and thorough
list of legislative actions involving emergency contraception. The Pharmacy Access
Partnership, Legislation, http://www.go2ec.orgfLegislation.htm (last visited Mar. 22,
2006). For a summary of legislation on pharmacy access to EC, see Pharmacy Access
Partnership, Current Pharmacy Access to EC (Aug. 15, 2005), http://www.go2ec.
org/pdfsALegislationSummary08l505.doc.
254. The United States Constitution guarantees that "[n]o state shall make or enforce
any law which shall abridge the privileges or immunities of citizens of the United States;
... nor deny to any person within its jurisdiction the equal protection of the laws." U.S.
CONST. amend. XIV, § 1. Statewide protocols and collaborative practice agreements that
undermine the intent of federal legislation may be unconstitutional under field
preemption. However, one commentator describes the ambiguities of 21 U.S.C. § 353
(b)(1)(B)(1), which grants prescribing authority to "a practitioner licensed by law to
administer such drug," as the justification for states to determine who has prescribing
authority under Amendment X. See Field, supra note 7, at 224 n.317 (quoting 21 U.S.C.
§ 353(b)(1) (1994) and indicating that the language quoted above replaces a list of
professionals authorized to prescribe drugs); see also Phyllis Coleman & Ronald A.
Shellow, Extending Physician's Standard of Care to Non-Physician Prescribers: The Rx
for Protecting Patients, 35 IDAHo L. REv. 37, 63-67 (1998) (presenting arguments for and
against extending prescribing authority to pharmacists and other healthcare providers).
255. See GAO REPORT, supra note 10, at 11 (naming such a third category of drugs,
"pharmacist-only" drugs, as distinct from the current and existing two categories of
prescription and over-the-counter drugs).
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prescription.256 However, in many countries there is a third clas-
sification of drugs, those that are available without a prescription
but only through a pharmacist.25 ' A pharmacist-only drug class
allows access to certain medications without a prescription, but
requires consultation with a pharmacist.25 The State of Florida has
a similar, de facto, system on the books;259 however, due to practical
considerations, it is almost never utilized. Table 2 provides a
suggested list of determinative criteria for the inclusion of drugs in
a pharmacist-only class."
Pharmacists in the United States have been advocating for a
third class of federal drug regulation for some time, with no avail.261
Recently, the American Pharmacist Association (APhA) has made
a strong push for such a third class. 2 The APhA convened a task
force in August 2004 to develop recommendations for a "Pharmacy
256. The term 'legend drug" is synonymous for prescription drug. See, e.g., Field,
supra note 7, at 224 n.317 (discussing the Durham-Humphrey Amendments to the
FDCA, specifically their modification regarding who may prescribe legend drugs). After
1951, all prescription drugs required the statement: "Caution: Federal Law prohibits
dispensing without a prescription." Pub. L. No. 82-215, 65 Stat. 648, 649 (1951) (prior to
1997 amendment). This phrase was subsequently changed to "Rx Only." FDA
Modernization Act of 1997, Pub. L. No. 105-115, § 126, 111 Stat. 2296, 2327 (1997)
(current version codified at 21 U.S.C. § 353(b)(4)(a) (2005)).
257. See GAO REPORT, supra note 10, at 24 tbl.2.1 (listing countries that have a
pharmacist-only class of drugs, including Australia, Ontario, Denmark, France,
Germany, Italy, the Netherlands, Switzerland, and the United Kingdom). Examples of
drugs included in this class are; orlistat (Xenical®) for weight loss, Australia;
acetaminophen (Tylenol®) with small quantities of codeine, Canada; lovastatin
(Mevacor®) for high cholesterol, England; fluticasone (Flonase®) for allergic rhinitis,
New Zealand. In the United States these drugs are prescription-only. Id.
258. See GAO REPORT, supra note 10, at 45-47 (describing the counseling
requirements in countries with a pharmacist-only class of drugs).
259. See FLA. ADMIN. CODE ANN. r. § 64B16-27.220 (2005). This list of drugs is highly
outdated and includes a number of products already available without a prescription.
Naturally, pharmacists fear additional liability under this law.
260. These criteria should allow a regulatory agency, such as the FDA, to reasonably
evaluate a drug for inclusion in a "pharmacist-only" class of drugs based upon the
totality of the circumstances. These criteria take into account the strengths and
limitations of the pharmacist, the disease to be treated, and the attributes of the drug
under investigation. This is the first time these criteria have been delineated in
literature and the author looks forward to receiving comments and feedback on their
utility.
261. See Joseph A. Woelfel, Pharmacy Care OTC Status Supported but OTC Status
of Statins Denied, Detail Doc. #210201, 21 PHARMACIST'S LErTERPRESCRIBER'S LETTER
1 (Feb. 2005). In a recent undeclared vote involving the establishment of a third drug
class for statins, members of an FDA advisory committee favored the idea. Id.
262. See Am. Pharmacists Ass'n, APhA Pharmacy Care OTC Task Force Report of
Opening Meeting 1 (Jan. 12, 2005), available at http://www.aphanet.org/AM/Template.
cfm?Section=Home&CONTENTID=2810&TEMPLATE=/CM/ContentDisplay.cfm
[hereinafter PHARMACY REPORT].
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Care OTC" category of drugs.2"' These products would be regulated
similarly to traditional nonprescription drugs; however, they would
only be available in areas with pharmacists present for consul-
tation.2 64 Pharmaceutical manufacturers and insurance companies
are likely to be in favor of this system, as sales would be expected to
increase and insurance coverage to desist, as non-prescription drugs
are not covered.265
Lobbying groups, including the Consumer Healthcare Products
Association and the American Medical Association, have strongly
opposed this idea. The Consumer Healthcare Products Association
is concerned that a pharmacist-only class of drugs would restrict
consumer access through higher drug costs to consumers.266 The
American Medical Association opposes such a move, 267 perhaps
because of a perceived shift in responsibility from the medical to the
pharmacy profession. Others claim that a pharmacist-only class of
drugs would provide no additional benefit over the current system.2
The establishment of a third class of drugs has genuine benefits
beyond consumer access. One such benefit is the ability to limit and
track the sale of certain pharmaceuticals.269 For example, an increas-
ing number of pharmacies are restricting the sale of pseudoephedrine,
a common decongestant, because of the potential for it to be converted
into methamphetamine (crank) in makeshift clandestine labora-
tories.270 A number of states have already passed legislation limiting
pseudoephedrine sales,27' and Congress had been working to classify
263. Id.
264. Id.
265. See Spencer, supra note 182, at 1001-02.
266. Consumer Healthcare Prod. Ass'n, Third Class of Drugs, available at http://www.
chpa-info.org/web/press-room/newsreleases/2003/05_27_03_ThirdClass-of_Drugs.pdf
(last visited Mar. 22, 2006).
267. Id.
268. See Field, supra note 7, at 206.
269. This benefit would be particularly helpful to address concerns about the potential
for the abuse of products. See Food & Drug Admin., FDA Talk Paper: FDA Warns
Against Abuse of Dextromethorphan (DMX) (May 20, 2005), available at http://www.
fda.gov/bbs/topics/ANSWERS/2005/ANS01360.html (describing the serious and poten-
tially deadly consequences of abusing DMX, available OTC as a cough suppressant).
Some pharmacies are limiting the sale of DMX. Id. DMX is chemically related to codeine
and at high doses, has mild hallucinogenic actions. Id. DMX has been reported to cause
a number of deaths among teenagers and young adults when abused. Id.
270. See Leslie Earnest & Rong-Gong Lin II, Target Moves Sale of Cold Medications
to Pharmacy, L.A. TIMES, Apr. 20, 2005, at C1, available at http://www.latimes.com/
business/la-fi-targetl9aprl9,1,53115,printstorycoll=la-headlines-business.
271. See, e.g., H.B. 1347, 2005 Leg. (Fla. 2005) (limiting the amount of sole active
ingredient pseudoephedrine sales to three packages or nine base grams per customer
and requiring retailers to restrict customer access by displaying the product behind the
pharmacy counter); see also H.D. 2485, 73d Leg. Assemb., Reg. Sess. (Or. 2005)
(classifying ephedrine or pseudoephedrine as a Schedule III Controlled Substance).
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it as a Controlled Substance.272 Furthermore, on March 9, 2006,
President Bush signed the USA PATRIOT Improvement and
Reauthorization Act of 2005,273 which contained the Combat
Methamphetamine Epidemic Act of 2005. This act includes a
number of strict anti-methamphetamine provisions, restricting the
sale of ingredients necessary to make methamphetamine.274 Another
potential benefit of a third drug class is a reduction in healthcare
costs, achieved by decreasing unnecessary physician visits, 275 as
pharmacy consultations are not routinely billed." 6
It may be beyond the FDA's authority to create such a drug
class through regulation. 7 The establishment of a new class of
drugs may require an act of Congress27 acting under constitutional
authority. 9 Interestingly, Congress has requested information on
this subject and studied this topic in some depth. In 1995, the U.S.
General Accounting Office, the investigative arm of Congress, issued
272. See The Combat Meth Act 2005, H.R. 314, 109th Cong. § 104 (2005) (a federal
attempt to restrict consumer access to pseudoephedrine by classifying it as a Schedule
V Controlled Substance). The Drug Enforcement Agency (DEA) schedules drugs based
on medical use and potential for abuse. Schedules for Controlled Substances, 21 U.S.C.
§ 812 (2002). Schedule I drugs have no approved medical use, a high potential for abuse,
and a lack of accepted safety. Id. § 812(b)(1). Schedule II drugs have an accepted medical
use but a high potential for abuse, which may lead to severe psychological dependence.
Id. § 812(b)(2). Schedule III and IV drugs have moderate to limited potential for abuse.
Id. § 812(b)(3)-(4). Schedule V drugs have a low potential for abuse and generally include
antitussives (i.e., cough preparations) and antidiarrheals. Id. § 812(b)(5). Some Schedule
V drugs are available for nonprescription use. Id. These drugs must be dispensed by a
pharmacist and purchased by an adult eighteen years of age or older and are restricted
in quantity. See PHARMACY LAW DIGEST, supra note 172, at 130-32; see also Controlled
Substances Act, 21 U.S.C. §§ 881-966 (2005) (providing a complete list of controlled
substances and schedules); U.S. Drug Enforcement Agency, Drug Scheduling,
www.dea.gov/pubs/scheduling.html (last visited Mar. 22, 2006). Schedule changes can
be initiated by the DEA, the Department of Health and Human Services, or through a
petition by any interested party. See Tara Christine Brady, Comment, The Argument for
the Legalization of Industrial Hemp, 13 SAN JOAQUIN AGRIC. L. REV. 85, 99 (2003); see
also U.S. Drug Enforcement Agency, Controlled Substances Act, http://www.usdoj.
gov/dealagency/csa.htm (last visited Mar. 22, 2006).
273. Pub. L. No. 109-177, 120 Stat. 192 (2006).
274. Id.; see also Press Release, U.S. Drug Enforcement Agency (Mar. 9, 2006),
available at http://www.dea.gov/pubs/pressrellpr030906.html) (listing the key anti-
methamphetamine provisions).
275. See GAO REPORT, supra note 10, at 30 (citing a study finding a decrease in
physician visits following a switch to OTC status).
276. Although traditional pharmacy services are not routinely billed, there is a trend
toward pharmacists seeking reimbursement for their services. See generally, J.M.
Ganther, Third Party Reimbursement for Pharmacist Services: Why Has It Been So
Difficult to Obtain and Is It Really the Answer for Pharmacy?, 42 J. AM. PHAR. ASS'N 875
(2002).
277. See GAO REPORT, supra note 10, at 83.
278. See id.
279. U.S. CONST. art. I, § 8, cl. 3.
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a report on the value of a 'Pharmacist-Controlled Class."2 This
report, however, found no compelling data to support the creation
of this class,28' and the establishment of a pharmacist-only class of
drugs has not been implemented.
Today is far different from 1995. Since then, several drugs,
such as Zantac®, Claritin®, and Prilosec®, have become available
without a prescription, and their impact has been tremendous.282
Furthermore, there has been an increasing push for the availability
of certain drugs, such as statins. 3 and the diet drug orlistat,2" to be
available without a prescription, but the FDA has grappled with
their risks.285
There appears to be great utility for a third class of drug
regulation and minimal reasons opposing it. Pharmacists publicly
support such a class,28s and the time appears right.28 ' Pharmacists
have the experience and knowledge to address the multitude of
concerns regarding proper and reliable use, and pharmacists are
widely accessible. Furthermore, the establishment of a pharmacist-
only class of drugs could serve as a reasonable compromise between
two completely dichotomous views.
280. See GAO REPORT, supra note 10.
281. Id. at 3.
282. Patrick W. Sullivan & Michael B. Nichol, The Economic Impact of Payer Policies
After the Rx-to-OTC Switch of Second-Generation Antihistamines, 7 VALUE IN HEALTH
402 passim (2004).
283. Statins are used for high cholesterol and have proven to reduce cardiovascular
mortality in diverse populations. G. De Angelis, The Influence of Statin Characteristics
on Their Safety and Tolerability, 58 INT'L J. CLINICAL PRAC. 945 passim (2004). Statins
include Crestor®, Lescol®, Lipitor®, Mevacor®, Pravachol®, and Zocor®. There are,
however, serious adverse drug reactions associated with statins including muscle
toxicity, liver toxicity, and numerous drug-drug interactions. Id. at 949-52. These drugs
have also been associated with a number of birth defects and are generally
contraindicated in pregnancy.
284. Anna Wilde Mathews, Glaxo Diet Drug Is Backed by Panel; FDA Advisory
Committee Supports Bid to Sell Orlistat Without a Prescription, WALL ST. J., Jan. 24,
2006, at D6.
285. During a joint meeting, two FDA advisory committees voted twenty to three
against selling Mevacor®, a statin, over the counter. Hilda F. Scharen, Joint Meeting of
the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic
Drugs Advisory Committee 2, 5-6 (Jan. 13-14, 2005) (summary minutes), available at
http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4086Ml.pdf. Some members
expressed a desire for an "in-between option" of prescription and non-prescription drug
regulation, whereby the product could be purchased without a prescription, but only
after speaking to a pharmacist. Id. at 6; see also Anna Wilde Mathews, Glaxo Gets Tough
FDA Questions over Bid for OTC Sale of Diet Drug, WALL ST. J., Jan. 21, 2006, at A6
(identifying concerns regarding drug-drug interactions with Orlistat).
286. See PHARMACY REPORT, supra note 262.
287. Rita Rubin, Rx out of the Box, USA TODAY, Feb. 8, 2005, at 1D.
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V. PLAN B® AND PHARMACIST-ONLY REGULATION
A. Practical Considerations
The complex regulatory framework surrounding EC poses many
obstacles and a tremendous opportunity for this country. Pharma-
cists have been looking to expand their role past "pill counters" for
many years, and EC appears to provide an ideal opportunity to
launch a pharmacist-only class of drugs.2"
The Plan B® application is nonprescription for adolescents
sixteen years of age and older and prescription for patients younger
than sixteen.28 9 The distinction is pragmatically inconsequential;
anybody who wants to purchase the product will be able to do so,
because the system can be easily circumvented. Moreover, this
system forces pharmacists into an adversarial role because they
must refuse to sell the product to underage girls. Additionally, the
question of whether supermarkets, convenience stores, and even gas
stations could litigate to sell Plan B® remains unanswered, as there
is no legal precedent or legislation addressing this issue.
EC is an ideal candidate for a pharmacist-only class of drugs
based on the controversial issues at hand. EC is extremely safe and
effective and is important for public health.29 ° Furthermore, world-
wide experience with EC is significant since more than thirty
countries allow its sale without a prescription.29 Pharmacists in
this country are in an ideal position to address the critical time
constraints of EC since they are accessible twenty-four hours a day,
seven days a week in many markets. Additionally, since statins and
their associated risks have been increasingly mentioned for non-
prescription use, both classes could be launched simultaneously,
shifting some of the media coverage.292
288. Id.
289. See Plan B Status Delayed, supra note 216.
290. See Grimes, supra note 37.
291. Health Canada Gives Canadian Women a Plan B, CANADA NEWS WIRE, Apr. 20,
2005, available at http://www.newswire.ca/en/releases/archive/Apri2005/2O/c7796.html
(reporting that Health Canada approved Plan B for use without a prescription).
Emergency contraception was first available without a prescription in 1999 when France
approved Norlevo (0.75 mg levonorgestrel). See The Dedicated Product NorLevo Is Now
Available over the Counter in France, NOT-2-LATE.CoM, http://ec.princeton.edu/news/
newsnorlevo.html. Emergency contraception is also available without a prescription in
Australia, New Zealand, Norway, and the United Kingdom, among other countries. See
Wikipedia, Emergency Contraception, http://en.wikipedia.org/wiki/Emergency-
contraception. Canada was the most recent country to approve emergency contraception
without a prescription when Health Canada approved Plan B® on April 20, 2005. See
Health Canada Gives Canadian Women a Plan B, supra.
292. See Woelfel, supra note 261. Despite safety concerns associated with statin use,
simvastatin (Zocor® Heart Pro) has recently become available in England without a
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B. Conscientious Objection
There are important obstacles to establishing a pharmacist-only
class of drugs for EC. Ironically, one of these barriers is the phar-
macist himself. Over the past few years, a growing number of
pharmacists have relied on conscientious objection when refusing to
dispense birth control and EC.293 In 1998, the APhA issued a
committee report recognizing the right to conscientious objection for
pharmacists.294
Conscientious objection is the moral or religious justification for
refusing to act against one's own belief.295 For example, a pharma-
cist may refuse to sell EC based on his "conscientious objection" if
he feels it is wrong or against his religious beliefs.296 Currently,
forty-seven states have passed conscientious objection legislation,
commonly referred to as refusal laws, supporting healthcare
providers.29 v Most of these laws, however, were not intended for
pharmacists and deal with abortion.2 ' Still, several states permit
healthcare providers to conscientiously refuse to provide contracep-
tion, and further legislation is pending in ten other states.299
Amazingly Wal-Mart, the nation's leading retailer, even had a
corporate policy to refuse to sell Plan B® since 1999.00 Under in-
creasing pressure to dispense emergency contraception, however,
they reversed that decision on March 3, 2006.301 Nevertheless,
Wal-Mart and its warehouse division, Sam's Club, maintain a
conscientious objection policy permitting its pharmacists to refer
prescription and many are advocating its sale in the U.S. without a prescription if a
similar behind-the-counter system is available. Id.
293. See generally Julie Cantor & Ken Baum, The Limits of Conscientious Objection
- May Pharmacists Refuse to Fill Prescriptions for Emergency Contraception?, 351 NEW
ENG. J. MED. 2008 (2004).
294. See APHA CONSCIENCE CLAUSE, supra note 8, at 10.
295. See Cantor & Baum, supra note 293, at 2009.
296. See Herbe, supra note 27, at 86 (providing a synopsis of the teachings of the
Roman Catholic Church).
297. Andis Robeznieks, Battle of the Conscience Clause: When Practitioners Say No,
AM. MED. NEWS, Apr. 11, 2005, available at http://www.ama-assn.org/amednews/2005/
04/11/prsa0411.htm.
298. Id.
299. Editorial, Moralists at the Pharmacy, N.Y. TIMES, Apr. 3, 2005, § 4, at 12,
available at http://query.nytimes.com/gst/abstract.html?res=F5OE16FB3A5BOC708C
DDAD0894 DD404482&incamp=archive:search.
300. Dana Canedy, Wal-Mart Decides Against Selling a Contraceptive, N.Y. TIMES,
May 14, 1999, at C1.
301. See Press Release, Wal-Mart, Wal-Mart to Carry Plan B Contraception,
http://walmartstores.com/GlobalWMStoresWeb/navigate.do?catg=512&contld=6074 (last
visited Mar. 22, 2006). State laws in Illinois and Massachusetts require pharmacies in
the state to sell Plan B®, and New York and Connecticut are working on similar laws. Id.
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patients with prescriptions for Plan B® to another pharmacy.0 2
Thus, even if Plan B® became available without a prescription, its
unimpeded access may remain a problem for some.3" 3 One pharma-
cist recently made news after refusing to fill, transfer, or return a
prescription for birth control for a University of Wisconsin student
at a K-Mart pharmacy.0 4 In another matter, four pharmacists in the
state of Illinois sued Walgreen after being placed on unpaid leave
and offered jobs in another state for failing to sign a statement
ensuring that they would dispense EC under a valid prescription,
citing protection under the state right of refusal law.30 5 The
plaintiffs in this case were being represented by the American
Center for Law and Justice, founded by Yale Law School graduate
and evangelist, Pat Robertson.06 Moreover, in Hellinger v. Eckerd
Corp., the court held that the plaintiff established a prima facie case
of religious discrimination under Title VII of the Civil Rights Act of
1964 when an employer fired a pharmacist for refusing to sell
contraception (e.g., condoms) because of his religious beliefs. 3 7 Even
if a pharmacist-only class of drugs came to fruition, legal issues
remain about the ability to require pharmacists to participate and
dispense drugs against their moral or religious beliefs.
Alternatively, the Governor of Illinois has recently filed a
rule requiring pharmacists in that state to dispense EC without
question. 30 Federal lawmakers have unveiled a bill in Congress
permitting a pharmacist to refuse to dispense this medication
302. Id.
303. See THE COUNCIL OF THE CITY OF N.Y., EMERGENCY CONTRACEPTION: AVAILABLE
AT YOUR PHARMACY YEr? (2004), available at http://www.nyc.gov/html/records/pdf/
govpub/872emergpills.pdf. This report shows that more than twenty-five percent of the
city's pharmacies were not stocking EC and some boroughs were less likely to stock it
than others. Id. at 8-9. The pharmacies not stocking EC were in violation of a local law
requiring pharmacies to post notice that they do not stock EC. Id. at 14.
304. Pharmacist Neil Noesen was ordered by an administrative law judge to take a
six-hour course in pharmacy ethics, had his license restricted for two years, and had to
pay legal fees of approximately $20,000 for "unprofessional conduct." See Press Release,
Planned Parenthood Advocates of Wisconsin, Pharmacist Punished for Denying Patient
Access to Birth Control (Apr. 13, 2005), available at http://www.ppawi.org/media/
PPAWI/Media/NoesenReprimanded.4-13-05.htm. The pharmacist could have likely
avoided these penalties if he had simply returned the prescription citing his
conscientious objection and referred her elsewhere.
305. See Julie Ingwersen, US Pharmacists Sue Walgreen over Contraceptive, REUTERS
HEALTH INFO., Jan. 30, 2006, available at http://www.medscape.com/viewarticle/522604.
306. See American Center for Law & Justice, History of ACLJ, http://www.aclj.org/
About/default.aspx?Section=10 (last visited Mar. 22, 2006).
307. 67 F. Supp. 2d 1359, 1360-61 (S.D. Fla. 1999) (denying defendant's motion for
summary judgment).
308. Monica Davey, Illinois Pharmacies Ordered to Provide Birth Control, N.Y. TIMES,
Apr. 2, 2005, at A10.
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provided another pharmacist is available to fill these types of
prescriptions.0 9
Another concern regarding a pharmacist-only class of drugs for
EC is a potential conflict of interest. Pharmacists would be selling
controversial products for which they may have a vested financial
interest. Imagine opening your Sunday newspaper and seeing a
coupon for Plan B® - buy one, get one free."' Or, worse yet, buy a
six-pack of beer and get Plan B® for free. Also, requiring consulta-
tion with a pharmacist may heighten concerns of embarrassment,
shame, or fear among women, which would otherwise be absent if
they could purchase it directly without the pharmacist. Moreover,
with increased responsibility, pharmacists may be subject to increas-
ed liability, which may prevent them from actively participating in
such a program. Additionally, certain states may repudiate a federal
class by implementing more stringent drug laws or specifically pro-
hibiting EC without a prescription.1 1 Finally, critics argue that EC
encourages unprotected sexual intercourse and thus increases the
spread of sexually transmitted disease, although the available data
suggest otherwise.312
CONCLUSION
Plan B® is safe and effective for OTC use.313 Furthermore, the
data suggests that it can be used appropriately in a nonprescription
309. This bill, called the Workplace Religious Freedom Act, is supported by a
bipartisan group of senators and representatives. See Rick Santorum & John Kerry,
Religion in the Pharmacy, N.Y. TIMES, Apr. 12, 2005, at A20.
310. Barr Pharmaceuticals, however, has indicated that if Plan B® is approved for
nonprescription use, they will not offer any coupons, samples, rebates, or trial offers. See
Joint Committee Report, supra note 2, at 92-93. Advertising of nonprescription drugs is
regulated very differently than advertising of prescription drugs. Advertising of
nonprescription drugs and dietary supplements (i.e., herbs) is regulated by the Federal
Trade Commission, whereas prescription drug advertising is regulated by the FDA. Fred
Sheftell et al., Direct-to-Consumer Advertising of OTC Agents Under Current FTC
Regulations: Concerns and Comment, 41 HEADACHE 534, 534 (2001) (expressing concern
for consumer safety due to the FTC & regulation of OTC advertising).
311. If a state law is more stringent than the federal law, it will be enforceable as long
as there is no conflict between the two (conflict preemption), or the federal law is not so
pervasive to leave no room for state regulatory control (field preemption). See Pharm.
Research & Mfrs. of Am. v. Concannon, 249 F.3d 66, 74 n.6, 74-75 (1st Cir. 2001).
312. See Raine et al., supra note 7, at 55, 58-62 (presenting clinical data suggesting
that pharmacy access and advanced provision of emergency contraception have no
significant effect on unprotected intercourse or the risk of sexually transmitted diseases).
313. Anna Glasier & David Baird, The Effects of Self-Administering Emergency
Contraception, 339 NEw ENG. J. MED. 1, 4 (1998) (presenting research finding that Plan
B® is safe and may prevent unwanted pregnancies).
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setting.314 However, Plan B® symbolizes something else - a grow-
ing schism in our social system. Pro-life activists view EC as an
abortifacient and its use as the killing of an unborn child.315 They
believe that increasing access to EC will condone its use and
diminish social responsibility. 16 Meanwhile, pro-choice activists
view EC as an integral part of a woman's choice and a necessary
option to prevent unwanted pregnancy.317 Nevertheless, the FDA
has already approved EC in this country.318
The current regulatory framework seems unable to deal with
the subtle nuances involving EC and the escalating push to have it
available without a prescription. It is becoming increasingly
apparent that the two-class distinction (prescription and nonpre-
scription) is incomplete and fails in this situation. The public outcry
regarding EC has been remarkable, with strong advocates on both
sides. Furthermore, a growing number of states have ventured into
their own regulatory systems,319 which undermine the current
federal system.
Approval of EC under a third class of drug regulation, a
pharmacist-only class, is an appropriate and viable solution. More-
over, it is greatly preferable to the evolving statewide protocols and
collaborative practice agreements currently in place. Women in this
country cannot rely on the states for such an important matter
regarding privacy rights. We have already seen states like Texas
enforce sodomy laws32 ° while even more "liberal" states, such as
Oregon, outlaw gay marriage.2 The FDA decided long ago that EC
is safe, reliable, and effective, and now it should have full faith and
credit in their decision. A growing segment of the public is in need of
EC and the best way to ensure its access is through the pharmacist.
314. See id.; see also Raymond et al., supra note 196, at 21.
315. See supra notes 62-63, 249 and accompanying text.
316. See Grimes, supra note 37, at 846-47.
317. See id. at 847.
318. See Notice, 62 Fed. Reg. 8610 (Feb. 25, 1997); ELECTRONIC ORANGE BOOK, cupra
note 65, at http://www.fda.gov/cder/orange/obannual.pdf (last visited Mar. 22, 2006);
Plan B Prescribing Information, supra note 11.
319. See supra Part III.C.
320. See Lawrence v. Texas, 539 U.S. 558, 562-63, 579 (2003) (reversing, six to three,
the Texas Court of Appeals, which had upheld the enforcement of a Texas statute
making engaging in homosexual conduct illegal).
321. Kate Zernike, Groups Vow Not to Let Losses Dash Gay Rights, N.Y. TIMES, Nov.
14, 2004, at A13 (noting that Oregon's marriage amendment ballot measure passed with
fifty-seven percent of the vote).
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Table 1. Over-the-Counter Drug Criteria
Drug is safe for self-treatment
Drug is effective with self-treatment
Potential for misuse and abuse is low
Potential for drug-drug interactions is low
Condition is self-diagnosable (i.e., symptomatic)
Condition is self-treatable
Condition is self-limiting
Product labeling can provide adequate directions for use
Drug has widespread experience, domestic or international
Condition should be non-life threatening
Condition is short-lived
Condition should not mask a more serious underlying disorder
Drug has an acceptable safety margin
Table 2. Pharmacist-Only Drug Criteria
Drug is generally safe if taken as directed but has the poten-
tial for serious adverse effects and harm
Drug is effective for treatment
Drug has the potential for abuse and misuse if sold or used
unregulated
Drug has the potential for clinically significant drug interac-
tions
Condition may or may not be self-diagnosable (i.e., symptom-
atic)
Condition is self-treatable
Condition may or may not be self-limiting
Drug treats a condition that could be dangerous or life-threat-
ening if not managed
Product labeling may be somewhat complicated for the typical
user to understand or comply with
Drug has widespread experience, domestic or international
Pharmacist is able to identify appropriate indications for
therapy
Drug has important contraindications the pharmacist is able
to assess
Pharmacist can recognize or ascertain patients who meet
criteria for use
Pharmacist can recognize or ascertain patients who fail to
meet criteria for use
Pharmacist is able to monitor or recommend appropriate
monitoring to the patient
Pharmacist can identify the need for referral to a physician
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Drug has the potential for inappropriate use which may be
harmful to society or the individual
Drug has few or no "off-label" uses
Drug has been deemed socially important
Drug has an acceptable safety margin
